UW–Madison SDAC

Sample Closed Session DMC Report

June 1, 2010

Statistical Data Analysis Center

Department of Biostatistics and Medical Informatics
University of Wisconsin–Madison

Contents

List of Figures and Tables

Part I

Introduction

1 Introduction

The University of Wisconsin Statistical Data Analysis Center (SDAC), part of the Department of Biostatistics and Medical Informatics, works to promote statistical practice, applications, and research in the design and analysis of clinical trials. SDAC serves as an independent biostatistics group providing interim analyses of accumulating data from ongoing clinical trials for review by independent data monitoring committees (DMCs).

We have prepared this sample DMC report based on simulated trial data in order to provide an example of a DMC report that can be shared externally.

2 Overview of Trial Protocol and Procedures

The *Introduction* to a typical DMC report begins with a brief overview of the trial design, including the treatment arms, planned sample size, and randomization scheme. Primary and secondary endpoints of the trial are listed. Summaries of eligibility criteria, study procedures, dosing regimen, and visit schedule are provided.

In this sample report, simulated datasets are used to represent a multi-center randomized clinical trial with 775 subjects in two treatment arms. Data are presented at baseline and from follow-up visits occurring every three months.

3 Overview of Report

This report has been prepared as a representative sample of the style of report prepared by SDAC for the Data Monitoring Committee of an ongoing clinical trial. The report illustrates the typical structure of a DMC report and provides specific examples of common data displays and page layouts.

There are two versions of this report. This version, the *Closed Session Report*, includes comparisons by assigned treatment and, for a real trial, would be viewed only by the DMC, SDAC, or others determined by the DMC. The other version, the *Open Session Report*, summarizes the data for all subjects, aggregated across treatment groups, and is intended for use by the Sponsor and other parties involved in the conduct of the study at the discretion of the Sponsor or the DMC.

Purpose of Report

The purpose of a DMC report is to summarize enrollment, selected baseline characteristics, adverse events, laboratory assessments, other safety measures and study endpoints as of the date of data transfer to SDAC. Modifications in study design and conduct may be recommended by the DMC if there are problems in these areas.

Report Production

SAS[1] and R[2] were used to perform the analyses and create the graphics and tables for the report. The document was typeset with LaTeX 2_ε.[3]

List of Abbreviations

ACE	Angiotensin-Converting Enzyme
AE	Adverse Event
BMI	Body Mass Index
CABG	Coronary Artery Bypass (Graft) Surgery
CHD	Coronary Heart Disease
CRF	Case Report Form
DMC	Data Monitoring Committee
ECG	Electrocardiogram
HDL	High-density Lipoprotein
HF	Heart Failure
IP	Investigational Product
IVRS	Interactive Voice Response System
LDL	Low-density Lipoprotein
LFT	Liver Function Test
LLN	Lower Limit of Normal
LVEF	Left Ventricular Ejection Fraction
MedDRA	Medical Dictionary for Regulatory Activities
MI	Myocardial Infarction
NYHA	New York Heart Association
SAE	Serious Adverse Event
SDAC	Statistical Data Analysis Center
ULN	Upper Limit of Normal

Abbreviated Report Outline

This sample report contains the following sections and chapters:

- Introduction
- Main Material
  - Accrual and Study Status
  - Baseline Characteristics
  - Adverse Events

[1] SAS Institute Inc.

[2] R Development Core Team (2005). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. URL `http://www.R-project.org`.

[3] LaTeX3 Project Team (2001). *LaTeX 2_ε for Authors*. URL `http://www.latex-project.org`.

  - Central Laboratory Measures
  - Other Follow-up and Safety Measures
  - Study Endpoints
- Supporting Material

Sources of Data Included in Report

All data presented in this sample report have been randomly generated and do not reflect the results of actual research studies past or present.

In an actual DMC report, this section would describe the data files received from one or more sources (e.g., CRF datasets from the clinical study database, SAE listings from a safety database, enrollment files from an IVRS, etc.). The type of file(s) obtained from each source, and the method and date of transfer, would be noted.

4 Report Structure

Treatment Labels

In the *Closed Session Report*, treatment groups are identified by the codes “A” and “B”. The assignment of codes to treatment arms would be provided verbally to DMC members upon request. Codes are consistent across reports throughout a trial.

P-values

P-values for treatment comparisons in this report appear as “p.A.B”. These *p*-values should be viewed as screening tools *only* because no adjustment has been made for multiple tests performed. Given the large number of tests to be considered, it would be expected that a number of *p*-values will appear statistically significant (< 0.05) simply by chance.

P-values for continuous or ordered categorical data are computed using the nonparametric Kruskal-Wallis test. This test is appropriate for data with nonnormal distributions and has power near that of the Student’s *t*-test when the data are normal. Pearson’s chi-square test is used for dichotomous (e.g., gender) and unordered (e.g., race) categorical data. The log-rank test is used to obtain *p*-values for time-to-event endpoints.

Graphical Conventions

The primary mode of presentation in this report is graphical. The visual presentation allows the reviewer to easily examine the distribution of the data items and characterize the study population(s) at a glance. Treatment comparisons, both at baseline and over time, are easily examined, as are

time-related trends in the data. The majority of figures present categorical data as bar charts, continuous data represented as boxplots, or time-to-event data presented as Kaplan-Meier estimates of survival curves.

Bar charts. Bar charts indicate for categorical data the number or percent of subjects by category. A simple bar chart such as the one for gender in Figure DEMO–1 on page 22, is used to display a single categorical variable with mutually exclusive categories. Bar charts of related dichotomous variables are sometimes grouped together to form a multiple bar chart, as in the display of baseline medical conditions in Figure MDHX–1 on page 23. A more detailed bar chart is used to display categorical data which has additional ordered subdivisions, as in the display of liver function test elevations in Figure LFTABN–1 on page 36.

Boxplots. Boxplots indicate the distribution of continuous data based on percentiles (for example, the display for age in Figure DEMO–1 on page 22). The top and bottom edges of the box represent the 25th and 75th percentiles of the data. The 5th and 95th percentiles are represented by the "whiskers" extending from the top and bottom of the box. The plotting symbol inside the box represents the median of the data.

Kaplan-Meier plot. Dichotomous response variables such as death for subjects with variable lengths of follow-up are often displayed as Kaplan-Meier (product-limit) "survival" curves across time. These curves indicate the cumulative probability of experiencing an event, or of remaining event-free, as a function of time since randomization (for example, see Figure SAE–1 on page 27). The total number of events appear on the plot, as do the numbers of subjects at risk (event-free and uncensored) at various points of follow-up.

Relative risk graphic. A relative risk graphic, for example, Figure ENDPT–2 on page 55, is used to efficiently summarize subgroup analyses of a treatment group difference of a time-to-event response variable. This graphic displays point estimates (black box) and nominal 95% confidence intervals (solid line) for the relative risk (hazard ratio) of an event in one treatment group compared to another treatment group. Estimates are obtained using the Cox proportional hazards model.

Change from baseline. For variables which are measured at several fixed time points, change from baseline is usually provided below the figure for the observed data. For continuous variables, change can be given either in the original units or as percent change (see Figure VIT–3 on page 48). For dichotomous variables, change from baseline can be indicated by displaying follow-up data separately for each baseline group.

Annotations. Figures indicate the number of subjects used for the analysis, either directly under the corresponding portion of the plot, or labeled as "nA" or "nB" at the bottom of the panel. In the *Closed Session Report*, *p*-values corresponding to the comparisons of the treatment groups are included, where applicable. Figures are also annotated with the data source.

Figure identifier. In the top right corner of each page of figures will be a mnemonic figure identifier. These identifiers, which are listed alphabetically in the index at the back of the report, normally would not change over the course of the study and hence can be useful for locating corresponding figures in future or past reports.

5 Notes on Chapter Contents

This section of a report *Introduction* contains additional details about analysis conventions and the contents of specific chapters.

General Conventions

This sample report is based on simulated data. An actual DMC report includes data from all randomized subjects. This section would include a brief description of data-handling and analysis conventions used in the report: e.g., how the sample sizes or demoninators were determined for various chapters (all randomized subjects, or all subjects with a particular data element available), how a “Baseline” record was identified for display if multiple records were present, and censoring conventions for time-to-event analysis.

Interim analyses are frequently based on incomplete and inconsistent data. The assumptions, computations and conventions designed to handle the data problems encountered during preparation of the report would be described in this section, or in the more detailed chapter notes below.

Accrual and Study Status

This chapter begins with Figure ACCR–1 on page 12, a display of subject accrual over time, based on a simulated enrollment dataset. Displays of the number of clinical centers enrolling subjects over time (based on date of first subject enrollment) are often included in this chapter. For multinational studies, accrual by country, continent, or other geographic region could be displayed.

Information on data availability or follow-up status of enrolled subjects, as in Figures STAT–1 on page 17 through STAT–4 on page 20, is also typically presented. These graphics can be help assess the disposition of study subjects as well as the timeliness of data collection and entry.

Baseline Characteristics

A typical report displays treatment group comparisons for a large number of baseline variables including demographics, medical history, vital signs, and other trial- or disease-specific factors. In this sample report, selected variables are presented based on simulated data, beginning with Figure DEMO–1 on page 22.

Adverse Events

This chapter contains some typical displays of adverse event (AE) data, based on simulated datasets. It begins with a summary of serious adverse events (SAEs) in Figure SAE–1 on page 27. An SAE is an event which is fatal, is life-threatening, requires or prolongs a hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is considered by the investigator to be a significant medical hazard.

In many clinical trials there is a separate mechanism for expedited reporting and data management of SAEs for regulatory purposes, with a subsequent reporting of the event on a study case report form. Because of the difficulty of merging data from different sources, information obtained from the SAE database is usually be displayed in a separate section. Information on the occurrence of SAEs is generally an important component of interim monitoring reports because of its greater timeliness and clinical significance.

Figures in this chapter provide summaries of SAEs, and of all AEs, overall and according to coded MedDRA system organ class terms and preferred terms. An actual DMC report might also include displays of specific event terms of interest in a trial, AEs considered to be related to investigational product (IP), or other analyses as appropriate.

Central Laboratory Measures

This chapter summarizes selected laboratory results recorded during screening and follow-up for randomized subjects. Typically in a clinical trial, blood samples are collected for hematology and chemistry assessments by a central laboratory at baseline and at specified times during follow-up. Results from any unscheduled or repeated lab tests are also recorded. Upper (ULN) and lower (LLN) limits of normal for each test, in some cases based on sex and/or age of the subject, are generally included in the laboratory data transferred to SDAC.

Figures LFTABN–1 on page 36, CHEMABN–1 on page 41 and HEMABN–1 on page 43 display the percentage of subjects with any post-randomization abnormal result for each measure. The denominators for percentages for each measure indicate the numbers of subjects with any post-randomization test results available for that measure.

The remaining figures in this chapter show measurements of selected tests by scheduled visit. Displays include absolute change from baseline and the percent of subjects with measurements above the ULN and/or below the LLN, as applicable, at each visit.

Other Follow-up and Safety Measures

Subject follow-up data may be collected by logging specified types of events (e.g., adverse events, hospitalizations, changes in dosing or concomitant medication), or by assessing subject status at designated visits or time points over the course of the follow-up period. The simulated datasets used to produce this sample report contain records for follow-up visits at 3, 6, 9 and 12 months after randomization.

Follow-up information can be displayed with bars representing the percent of subjects under observation who meet certain criteria at specified timepoints or with a boxplot to illustrate the distribution of continuous measures. Change from baseline is often presented on the same page, as displayed in Figure VIT–1 on page 46. For other types of data, such as concomitant medication in Figure CONMEDS–1 on page 52, the report summarizes information collected over the entire period of observation.

Study Endpoints

The Kaplan-Meier plot in Figure ENDPT–1 on page 54 displays all-cause mortality based on a simulated endpoint dataset. A relative risk graphic is also displayed, showing the treatment effect (hazard ratio) overall and for various baseline subgroups. Estimates of the hazard ratios and 95% confidence intervals were obtained using the Cox proportional hazards model.

A more extensive report would include analyses of secondary and other endpoints of interest. It might also contain Kaplan-Meier plots for subgroups of particular interest, displays of event classification resulting from an adjudication process, interim monitoring boundaries, and other items as appropriate for the trial.

Supporting Material

Part III, *Supporting Material*, contains back-up tables of univariate statistics and detailed frequency counts for the graphical displays of the previous chapters. These tables are cross-referenced to and from the corresponding graphical pages.

Ancillary Material

Additional information relevant to the interpretation of a report can be included as *Ancillary Material*. Early in a trial, copies of key study forms may be included to illustrate the source of certain data items or the data collection process in general. Detailed listings of subject accrual at each clinical center, reported serious adverse events, or other trial data may also be provided.

6 List of Key Participants

In an actual report, this final section of the *Introduction* would contain contact information for key study participants, including members of the Data Monitoring Committee, Sponsor personnel, SDAC, and others as appropriate. In this sample report, we provide contact information for SDAC.

Statistical Data Analysis Center (SDAC)

Department of Biostatistics and Medical Informatics
University of Wisconsin–Madison
WARF Office Building
610 Walnut Street
Madison, WI 53726–2397
Fax: (608) 263-0415
www.biostat.wisc.edu

Marian Fisher, PhD	(608) 263-7390
Director	fisher@biostat.wisc.edu
Gretchen Poulsen	(608) 265-6702
Program Manager	poulsen@biostat.wisc.edu

Part II

Main Material

Chapter 1

Accrual and Study Status

Figure ACCR–1



Information from a simulated enrollment dataset. The first subject was randomized on April 27, 2007.

Figure ACCR–2

Clinical Site Participation





Information from a simulated enrollment dataset. Clinical sites are included if they have randomized at least one subject.

Figure ACCR–3

Distribution of Subjects Across Clinical Sites



Information from a simulated enrollment dataset.

Figure ACCR–4



Information from a simulated enrollment dataset.

See Table Set ACCR–4 on page 57.

Figure ACCR–5

Country Participation

Randomization by Region and Country		Date First Subject Randomized	Most Recent Subject Randomized	Number of Sites Randomizing Subjects	Number of Subjects Randomized	Subjects Per Site (mean)
North America	**United States**	Apr 27, 2007	Apr 11, 2008	38	236	6.2
	Canada	Jun 12, 2007	May 28, 2008	15	104	6.9
	*** REGION TOTAL ***	Apr 27, 2007	May 28, 2008	53	340	6.4
Asia						
	Japan	May 1, 2007	Feb 26, 2008	5	32	6.4
	Hong Kong	May 4, 2007	Feb 29, 2008	3	17	5.7
	Korea	May 12, 2007	Apr 22, 2008	4	29	7.3
	Taiwan	Jun 8, 2007	Apr 9, 2008	3	24	8.0
	Philippines	Jul 23, 2007	Feb 17, 2008	3	15	5.0
	*** REGION TOTAL ***	May 1, 2007	Apr 22, 2008	18	117	6.7
Latin America						
	Chile	May 2, 2007	Mar 23, 2008	3	16	5.3
	Peru	May 27, 2007	Apr 8, 2008	3	18	6.0
	Mexico	Jun 27, 2007	May 8, 2008	3	24	8.0
	Brazil	Jul 29, 2007	Feb 23, 2008	3	19	6.3
	*** REGION TOTAL ***	May 2, 2007	May 8, 2008	12	77	6.6
Europe						
	Sweden	May 17, 2007	Feb 18, 2008	3	19	6.3
	Italy	May 21, 2007	Apr 5, 2008	3	23	7.7
	Norway	Jun 8, 2007	Feb 17, 2008	3	22	7.3
	Germany	Jun 25, 2007	May 24, 2008	5	39	7.8
	Finland	Jun 29, 2007	Mar 19, 2008	3	23	7.7
	Portugal	Jul 13, 2007	Mar 31, 2008	3	21	7.0
	United Kingdom	Jul 19, 2007	May 1, 2008	9	54	6.0
	Spain	Aug 1, 2007	Feb 13, 2008	4	21	5.3
	France	Sep 2, 2007	Mar 5, 2008	3	19	6.3
	*** REGION TOTAL ***	May 17, 2007	May 24, 2008	36	241	6.8
**** OVERALL ****		Apr 27, 2007	May 28, 2008	119	775	6.6

Information from a simulated enrollment dataset. The order of regions and countries in the table is determined by the date of first subject entry.

Figure STAT–1



Information from a simulated enrollment dataset. In the upper panel, subjects are assigned to the first applicable category. For data presented in the lower panels, investigators are asked to choose a single reason for each of withdrawal from treatment and withdrawal from study. Death information is taken from all available sources.

See Table Set STAT–1 on page 57.

Figure STAT–2



Information from a simulated enrollment dataset. These plots summarize the study status of randomized subjects by calendar time. The sample sizes displayed are the number of subjects randomized as of a given date.

See Table Set STAT–2 on page 58.

Figure STAT–3



Information from a simulated enrollment dataset. These plots summarize the study status of randomized subjects by day relative to randomization. In this display, a “month” is considered to be 30 days. The denominators for percentages are the number of subjects being followed at a given time.

See Table Set STAT–3 on page 59.

Figure STAT–4



Information from simulated enrollment, laboratory and vital signs datasets. A scheduled visit is “reported” if a record of it exists in the laboratory or vital signs datasets for a given subject. A visit is “expected, not reported” if the anticipated visit date (randomization date plus an appropriate time interval, e.g., 30 days) is at least 14 days earlier than the data cut-off date, but there is not a record in the laboratory or vital signs datasets.

See Table Set STAT–4 on page 60.

Chapter 2

Baseline Characteristics

Figure DEMO–1



Information from a simulated baseline dataset. For data on race, presented in the middle panel, subjects were asked to specify a single race category.

See Table Set DEMO–1 on page 61.

Figure MDHX–1



Information from a simulated baseline dataset.

See Table Set MDHX–1 on page 62.

Figure VITB–1



Information from a simulated vital signs dataset. A physical examination is performed at the screening visit and vital signs are recorded at both the screening and randomization visits. For vital sign measurements, the baseline value for each item is defined as the value recorded at the randomization visit if available, otherwise the screening value is used.

See Table Set VITB–1 on page 63.

Figure LABB–1



Information from a simulated laboratory dataset. The baseline value for each test is defined as the last measurement on or before the date of randomization, if more than one baseline assessment is recorded. This is a subset of laboratory measures that would typically be included in an actual DMC report.

See Table Set LABB–1 on page 64.

Chapter 3

Adverse Events

Figure SAE–1



Information from a simulated serious adverse events dataset. In the lower panel, follow-up time for subjects with no SAE is censored at the date of data cut-off or at the date of withdrawal from study, if applicable. The denominators for percentages include all randomized subjects. Events known to have begun prior to randomization are not included.

See Table Set SAE–1 on page 65.

Figure SAE–2



Information from a simulated serious adverse events dataset. The denominators for percentages include all randomized subjects. Events known to have begun prior to randomization are not included.

See Table Set SAE–2 on page 66.

Table SAETAB

SAEs by System Organ Class and Preferred Term

Serious Adverse Event	N Subjects (Events)			Percent of Subjects			P-Values
MedDRA System Organ Class ► Preferred Term	A	B	ALL	A	B	ALL	pA.B
Cardiac disorders	**30 (37)**	**28 (40)**	**58 (77)**	**7.7**	**7.2**	**7.5**	**0.793**
Angina pectoris	6 (7)	7 (8)	13 (15)	1.5	1.8	1.7	0.776
Angina unstable	4 (7)	7 (10)	11 (17)	1.0	1.8	1.4	0.360
Arrhythmia neonatal	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Atrial fibrillation	5 (6)	2 (3)	7 (9)	1.3	0.5	0.9	0.256
Bradycardia	1 (1)	2 (3)	3 (4)	0.3	0.5	0.4	0.561
Cardiac aneurysm	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Cardiac failure	2 (3)	2 (3)	4 (6)	0.5	0.5	0.5	0.998
Cardiac failure congestive	1 (1)	2 (2)	3 (3)	0.3	0.5	0.4	0.561
Cardiac perforation	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Cardio-respiratory arrest	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Coronary artery stenosis	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Hypertensive heart disease	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Intracardiac thrombus	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Left ventricular hypertrophy	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Myocardial infarction	2 (2)	0 (0)	2 (2)	0.5	0.0	0.3	0.157
Neonatal tachycardia	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Papillary muscle haemorrhage	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Pericardial disease	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Pneumopericardium	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Sinoatrial block	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Tachyarrhythmia	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Ventricular extrasystoles	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Ventricular fibrillation	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Ventricular tachyarrhythmia	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316

Information from a simulated adverse events dataset. The denominators for percentages include all randomized subjects. Events known to have begun prior to randomization are not included.

Figure AE–1



Information from a simulated adverse events dataset. Events known to have begun prior to randomization are not included.

See Table Set AE–1 on page 68.

Figure AE–2



Information from a simulated adverse events dataset. Panels display the percent of subjects experiencing any AE within each coded system organ class. The denominators for percentages include all randomized subjects. Events known to have begun prior to randomization are not included. Within each system organ class, a subject was assigned to a single category based on the AE with the maximum severity.

See Table Set AE–2 on page 69.

Figure AE–3



Information from a simulated adverse events dataset. Display includes the 30 most common coded preferred terms, determined by the number of subjects with each term reported. The denominators for percentages include all randomized subjects. Events known to have begun prior to randomization are not included. Preferred terms are sorted by overall frequency. Within each preferred term, a subject was assigned to a single category based on the AE with the maximum severity.

See Table Set AE–3 on page 71.

Table AETAB

AEs by System Organ Class and Preferred Term

Adverse Event	N Subjects (Events)			Percent of Subjects			P-Values
MedDRA System Organ Class ► Preferred Term	A	B	ALL	A	B	ALL	pA.B
Cardiac disorders	**89 (142)**	**70 (110)**	**159 (252)**	**22.9**	**18.1**	**20.5**	**0.095**
Accelerated idioventricular rhythm	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Angina pectoris	19 (29)	19 (30)	38 (59)	4.9	4.9	4.9	0.993
Angina unstable	15 (23)	9 (14)	24 (37)	3.9	2.3	3.1	0.216
Aortic valve disease mixed	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Aortic valve prolapse	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Arrhythmia neonatal	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Arteriospasm coronary	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Atrial fibrillation	11 (17)	7 (10)	18 (27)	2.8	1.8	2.3	0.343
Atrioventricular block	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Bifascicular block	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Bradycardia	1 (2)	4 (5)	5 (7)	0.3	1.0	0.6	0.177
Bradycardia neonatal	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Cardiac aneurysm	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Cardiac failure	5 (8)	4 (6)	9 (14)	1.3	1.0	1.2	0.740
Cardiac failure congestive	5 (9)	2 (2)	7 (11)	1.3	0.5	0.9	0.256
Cardiac failure high output	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Cardiac perforation	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Cardiac siderosis	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Cardiac valve disease	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Cardiac valve sclerosis	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Cardio-respiratory arrest	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Cardiomyopathy	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Cardiovascular deconditioning	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Coronary artery disease	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Coronary artery stenosis	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Cyanosis	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Dressler's syndrome	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Heart valve stenosis	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Hepatojugular reflux	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Hypertensive heart disease	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Intracardiac thrombus	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Intrapericardial thrombosis	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Kyphoscoliotic heart disease	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Left atrial hypertrophy	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Left ventricular dysfunction	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318
Left ventricular hypertrophy	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Low cardiac output syndrome	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Myocardial infarction	6 (10)	2 (4)	8 (14)	1.5	0.5	1.0	0.156
Myocardial ischaemia	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Neonatal tachycardia	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Papillary muscle disorder	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Papillary muscle haemorrhage	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Pericardial disease	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Pericarditis uraemic	1 (2)	0 (0)	1 (2)	0.3	0.0	0.1	0.318

(Continued on next page.)

Information from a simulated adverse events dataset. The denominators for percentages include all randomized subjects. Events known to have begun prior to randomization are not included.

AEs by System Organ Class and Preferred Term

Table AETAB (*cont.*)

(Continued from previous page.)

Adverse Event	N Subjects (Events)			Percent of Subjects			P-Values
MedDRA System Organ Class ► Preferred Term	A	B	ALL	A	B	ALL	pA.B
Pleuropericarditis	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Pneumopericardium	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Prinzmetal angina	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Pulmonary valve sclerosis	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Rhythm idioventricular	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Right ventricular dysfunction	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Silent myocardial infarction	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Sinoatrial block	0 (0)	1 (1)	1 (1)	0.0	0.3	0.1	0.316
Sinus bradycardia	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Supraventricular extrasystoles	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Supraventricular tachycardia	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Tachyarrhythmia	1 (1)	0 (0)	1 (1)	0.3	0.0	0.1	0.318
Tachycardia	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Ventricular extrasystoles	2 (3)	2 (2)	4 (5)	0.5	0.5	0.5	0.998
Ventricular fibrillation	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316
Ventricular tachyarrhythmia	0 (0)	1 (2)	1 (2)	0.0	0.3	0.1	0.316

Information from a simulated adverse events dataset. The denominators for percentages include all randomized subjects. Events known to have begun prior to randomization are not included.

Chapter 4

Central Laboratory Measures

Figure LFTABN–1

Summary of Liver Function Test Elevations



Information from a simulated laboratory dataset. This display summarizes the maximum post-baseline elevation for each subject, including repeated measurements and measurements recorded at unscheduled visits.

See Table Set LFTABN–1 on page 73.

Figure LFT–1



Information from a simulated laboratory dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

See Table Set LFT–1 on page 74.

Figure LFT–2



Information from a simulated laboratory dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

See Table Set LFT–2 on page 75.

Figure LFT–3

Aspartate Amino Transferase



Information from a simulated laboratory dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

See Table Set LFT–3 on page 76.

Figure LFT–4



Information from a simulated laboratory dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

See Table Set LFT–4 on page 77.

Figure CHEMABN–1



Information from a simulated laboratory dataset. Panels display the percent of subjects with any post-randomization value reported below the lower limit of normal (LLN) or above the upper limit of normal (ULN), as applicable, for each test, including repeated measurements and measurements recorded at unscheduled visits.

See Table Set CHEMABN–1 on page 78.

Figure CHEM–1



Information from a simulated laboratory dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed. In an actual DMC report, a similar page would be included for each laboratory measure.

See Table Set CHEM–1 on page 79.

Figure HEMABN–1



Information from a simulated laboratory dataset. Panels display the percent of subjects with any post-randomization value reported below the lower limit of normal (LLN) or above the upper limit of normal (ULN), as applicable, for each test, including repeated measurements and measurements recorded at unscheduled visits.

See Table Set HEMABN–1 on page 80.

Figure HEM–1



Information from a simulated laboratory dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed. In an actual DMC report, a similar page would be included for each laboratory measure.

See Table Set HEM–1 on page 81.

Chapter 5

Other Follow-up and Safety Measures

Figure VIT–1



Information from a simulated vital signs dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

See Table Set VIT–1 on page 84.

Figure VIT–2



Information from a simulated vital signs dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

■ A
○ B

See Table Set VIT–2 on page 86.

Figure VIT–3



Information from a simulated vital signs dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

See Table Set VIT–3 on page 87.

Figure ECG–1



Information from a simulated ECG dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

See Table Set ECG–1 on page 88.

Figure ECG–2

ECG: PR Interval and QRS Interval



Information from a simulated ECG dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

■ A
○ B

See Table Set ECG–2 on page 89.

Figure ECG–3

ECG: RR Interval and QTc Interval (Fridericia)



Information from a simulated ECG dataset. Baseline is defined as the last measurement on or before the date of randomization. For follow-up data in an actual report, multiple measurements may be available with the same visit label, in which case the first value would be displayed.

See Table Set ECG–3 on page 91.

Figure CONMEDS–1



Information from a simulated concomitant medications dataset. The denominator for percentages includes all subjects with any CRF data submitted. Medications which were terminated prior to randomization have been excluded.

See Table Set CONMEDS–1 on page 92.

Chapter 6

Study Endpoints

Figure ENDPT–1



Information from a simulated endpoint dataset. The risk set includes all randomized subjects. Follow-up time for subjects not reporting an event was censored on the day of data transfer, or the date of withdrawal from study, if applicable.

See Table Set ENDPT–1 on page 93.

Figure ENDPT–2



Information from simulated endpoint and baseline datasets. Hazard ratios for treatment B versus treatment A are based on univariate analysis using the Cox proportional hazards model. All *p*-values are from a log-rank test.

Part III

Supporting Material

Chapter 1

Accrual and Study Status

1.1 Accrual

Table Set ACCR–4

Geographic Distribution: Number of Subjects

See Figure ACCR–4 on page 15.

		Value							
	Total	North America		Europe		Asia		Latin America	
Trt	Subjs	N	%	N	%	N	%	N	%
TOTAL	775	340	43.87	241	31.10	117	15.10	77	9.94

Geographic Distribution: Number of Sites

See Figure ACCR–4 on page 15.

		Value							
	Total	North America		Europe		Asia		Latin America	
Trt	Subjs	N	%	N	%	N	%	N	%
TOTAL	119	53	44.54	36	30.25	18	15.13	12	10.08

1.2 Study Status

Table Set STAT–1

Study Status: Current Status of Randomized Subjects

See Figure STAT–1 on page 17.

		Value									
	Total	Dead		Withdrawn from study		On study, Off treatment		On study, On treatment			P-
Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
A	388	52	13.40	22	5.67	108	27.84	206	53.09	A.B	0.124
B	387	34	8.79	27	6.98	126	32.56	200	51.68		

Study Status: Reason Off Treatment

See Figure STAT–1 on page 17.

			Value					
		Total	Yes		No			P-
	Trt	Subjs	N	%	N	%	Contrast	Value
Subject died	A	388	31	7.99	357	92.01	A.B	0.081
	B	387	19	4.91	368	95.09		
Consent withdrawn	A	388	18	4.64	370	95.36	A.B	0.096
	B	387	29	7.49	358	92.51		
Lost to follow-up	A	388	12	3.09	376	96.91	A.B	0.368
	B	387	8	2.07	379	97.93		
Adverse event	A	388	66	17.01	322	82.99	A.B	0.225
	B	387	79	20.41	308	79.59		
Protocol violation	A	388	6	1.55	382	98.45	A.B	0.765
	B	387	5	1.29	382	98.71		
Pregnancy	A	388	0	0.00	388	100.00	A.B	1.000
	B	387	0	0.00	387	100.00		
Subject request	A	388	39	10.05	349	89.95	A.B	0.990
	B	387	39	10.08	348	89.92		
Other	A	388	10	2.58	378	97.42	A.B	0.637
	B	387	8	2.07	379	97.93		

Study Status: Reason Off Study

See Figure STAT–1 on page 17.

			Value					
		Total	Yes		No			P-
	Trt	Subjs	N	%	N	%	Contrast	Value
Subject died	A	388	50	12.89	338	87.11	A.B	0.037
	B	387	32	8.27	355	91.73		
Consent withdrawn	A	388	20	5.15	368	94.85	A.B	0.288
	B	387	27	6.98	360	93.02		
Lost to follow-up	A	388	4	1.03	384	98.97	A.B	0.414
	B	387	2	0.52	385	99.48		
Other	A	388	0	0.00	388	100.00	A.B	1.000
	B	387	0	0.00	387	100.00		

Table Set STAT–2

Status Summary by Calendar Time: Treatment A

See Figure STAT–2 on page 18.

		Value							
	Total	On study, on treatment		On study, off treatment		Withdrawn from study		Dead	
Date	Subjs	N	%	N	%	N	%	N	%
Jul 01 2007	16	16	100.0	0	0.0	0	0.0	0	0.0
Oct 01 2007	114	110	96.5	3	2.6	0	0.0	1	0.9
Jan 01 2008	303	271	89.4	20	6.6	2	0.7	10	3.3
Apr 01 2008	381	296	77.7	49	12.9	12	3.1	24	6.3
Jul 01 2008	388	242	62.4	83	21.4	17	4.4	46	11.9

Status Summary by Calendar Time: Treatment B

See Figure STAT–2 on page 18.

		Value							
	Total	On study, on treatment		On study, off treatment		Withdrawn from study		Dead	
Date	Subjs	N	%	N	%	N	%	N	%
Jul 01 2007	16	16	100.0	0	0.0	0	0.0	0	0.0
Oct 01 2007	114	106	93.0	6	5.3	0	0.0	2	1.8
Jan 01 2008	302	263	87.1	30	9.9	3	1.0	6	2.0
Apr 01 2008	378	285	75.4	66	17.5	12	3.2	15	4.0
Jul 01 2008	387	225	58.1	115	29.7	21	5.4	26	6.7

Table Set STAT–3

Status Summary by Time on Study: Treatment A

See Figure STAT–3 on page 19.

		Value							
	Total	On study, on treatment		On study, off treatment		Withdrawn from study		Dead	
Months	Subjs	N	%	N	%	N	%	N	%
0	388	387	99.7	0	0.0	0	0.0	1	0.3
1	388	367	94.6	13	3.4	0	0.0	8	2.1
2	388	343	88.4	27	7.0	5	1.3	13	3.4
3	386	322	83.4	38	9.8	7	1.8	19	4.9
4	384	305	79.4	50	13.0	7	1.8	22	5.7
5	373	281	75.3	60	16.1	7	1.9	25	6.7
6	355	251	70.7	62	17.5	11	3.1	31	8.7
7	324	220	67.9	59	18.2	14	4.3	31	9.6
8	277	173	62.5	54	19.5	16	5.8	34	12.3
9	220	130	59.1	50	22.7	12	5.5	28	12.7
10	149	89	59.7	37	24.8	8	5.4	15	10.1
11	89	53	59.6	21	23.6	8	9.0	7	7.9
12	50	36	72.0	9	18.0	2	4.0	3	6.0

Status Summary by Time on Study: Treatment B

See Figure STAT–3 on page 19.

		Value							
	Total	On study, on treatment		On study, off treatment		Withdrawn from study		Dead	
Months	Subjs	N	%	N	%	N	%	N	%
0	387	384	99.2	3	0.8	0	0.0	0	0.0
1	387	359	92.8	21	5.4	1	0.3	6	1.6
2	387	335	86.6	38	9.8	4	1.0	10	2.6
3	386	316	81.9	50	13.0	9	2.3	11	2.8
4	382	284	74.3	67	17.5	15	3.9	16	4.2
5	373	262	70.2	77	20.6	16	4.3	18	4.8
6	354	244	68.9	80	22.6	14	4.0	16	4.5
7	323	213	65.9	81	25.1	13	4.0	16	5.0
8	277	166	59.9	79	28.5	15	5.4	17	6.1
9	220	128	58.2	62	28.2	13	5.9	17	7.7
10	149	83	55.7	45	30.2	9	6.0	12	8.1
11	89	52	58.4	27	30.3	3	3.4	7	7.9
12	51	30	58.8	16	31.4	0	0.0	5	9.8

Table Set STAT–4

Data Availability by Visit: Scheduled Visits

See Figure STAT–4 on page 20.

			Value			
			Visit reported in database		Visit expected, not reported	
	Trt	Total Subjs	N	%	N	%
Baseline	TOTAL	775	775	100.00	0	0.00
Month 3	TOTAL	775	718	92.65	8	1.03
Month 6	TOTAL	775	592	76.39	33	4.26
Month 9	TOTAL	775	306	39.48	45	5.81
Month 12	TOTAL	775	58	7.48	18	2.32

Chapter 2

Baseline Characteristics

2.1 Demographics

Table Set DEMO–1

Baseline Characteristics: Age (years)

See Figure DEMO–1 on page 22.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	56.4	7.9	56.5	50.9	61.4	43.5	69.6
B	387	56.6	7.9	57.1	51.5	62.1	44.2	68.8

Baseline Characteristics: Gender

See Figure DEMO–1 on page 22.

		Value			
	Total	Male		Female	
Trt	Subjs	N	%	N	%
A	388	249	64.18	139	35.82
B	387	246	63.57	141	36.43

Baseline Characteristics: Race

See Figure DEMO–1 on page 22.

		Value							
	Total	Black		White		Asian		Other	
Trt	Subjs	N	%	N	%	N	%	N	%
A	388	27	6.96	263	67.78	81	20.88	17	4.38
B	387	36	9.30	246	63.57	88	22.74	17	4.39

Baseline Characteristics: NYHA Class

See Figure DEMO–1 on page 22.

		Value							
	Total	Class IV		Class III		Class II		Class I	
Trt	Subjs	N	%	N	%	N	%	N	%
A	388	10	2.58	147	37.89	231	59.54	0	0.00
B	387	6	1.55	139	35.92	242	62.53	0	0.00

Baseline Characteristics: Left Ventricular Ejection Fraction (%)

See Figure DEMO–1 on page 22.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	46.2	8.7	46.5	40.3	52.5	31.6	60.0
B	387	45.7	8.2	45.5	39.2	51.2	33.0	59.3

2.2 Medical History

Table Set MDHX–1

Medical History: Current or Prior History of Cardiovascular Conditions/Procedures

See Figure MDHX–1 on page 23.

	Trt	Total Subjs	Value: Yes N	Yes %	No N	No %
Prior myocardial infarction	A	388	103	26.55	285	73.45
	B	387	95	24.55	292	75.45
Coronary artery bypass surgery (CABG)	A	388	39	10.05	349	89.95
	B	387	34	8.79	353	91.21
Multivessel CHD	A	388	44	11.34	344	88.66
	B	387	50	12.92	337	87.08
Cerebrovascular disease or stroke	A	388	33	8.51	355	91.49
	B	387	29	7.49	358	92.51
Transient ischaemic attack	A	388	41	10.57	347	89.43
	B	387	46	11.89	341	88.11
Angina pectoris	A	388	94	24.23	294	75.77
	B	387	81	20.93	306	79.07
Hypertension	A	388	150	38.66	238	61.34
	B	387	129	33.33	258	66.67
Congestive HF	A	388	96	24.74	292	75.26
	B	387	109	28.17	278	71.83

Medical History: Current or Prior History of Other Relevant Conditions

See Figure MDHX–1 on page 23.

	Trt	Total Subjs	Value: Yes N	Yes %	No N	No %
Diabetes mellitus	A	388	70	18.04	318	81.96
	B	387	66	17.05	321	82.95
Smoker	A	388	87	22.42	301	77.58
	B	387	72	18.60	315	81.40
Family history of premature CHD	A	388	101	26.03	287	73.97
	B	387	104	26.87	283	73.13
Cancer	A	388	37	9.54	351	90.46
	B	387	30	7.75	357	92.25

2.3 Physical Examination

Table Set VITB–1

Baseline Physical Examination: Height (cm)

See Figure VITB–1 on page 24.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	169.8	11.4	168.8	162.0	177.7	152.5	189.1
B	387	170.0	11.6	169.6	161.4	177.9	151.4	189.4

Baseline Physical Examination: Weight (kg)

See Figure VITB–1 on page 24.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	86.9	12.0	86.7	79.4	95.0	68.3	106.1
B	387	87.1	12.8	86.7	79.1	95.4	64.9	108.5

Baseline Physical Examination: BMI (kg/mˆ2)

See Figure VITB–1 on page 24.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	30.5	5.6	30.0	26.7	34.1	21.8	40.4
B	387	30.5	6.0	29.9	26.3	34.4	21.3	40.4

Baseline Physical Examination: Waist-to-Hip Ratio

See Figure VITB–1 on page 24.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	0.99	0.15	0.99	0.90	1.10	0.74	1.24
B	387	1.00	0.16	0.99	0.88	1.11	0.73	1.28

Baseline Physical Examination: Systolic Blood Pressure (mmHg)

See Figure VITB–1 on page 24.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	129.8	9.8	130.1	122.5	136.0	113.6	146.6
B	387	129.9	9.7	130.3	122.6	136.7	114.7	146.5

Baseline Physical Examination: Diastolic Blood Pressure (mmHg)

See Figure VITB–1 on page 24.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	84.4	7.0	84.2	79.1	89.2	73.6	96.0
B	387	85.1	6.4	84.9	81.1	89.5	75.1	95.5

Baseline Physical Examination: Heart Rate (bpm)

See Figure VITB–1 on page 24.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	64.6	6.5	64.2	60.1	68.9	54.6	76.0
B	387	64.5	6.9	64.9	59.5	69.4	52.8	75.4

2.4 Laboratory Data

Table Set LABB–1

Baseline Liver Function Test Results: Alkaline Phosphatase (IU/L)

See Figure LABB–1 on page 25.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	79.3	36.6	74.0	63.0	85.0	45.0	114.0
B	385	77.8	28.5	73.0	63.0	85.0	49.0	132.0

Baseline Liver Function Test Results: Alanine Amino Transferase (IU/L)

See Figure LABB–1 on page 25.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	16.9	10.5	15.0	12.0	19.0	7.0	26.0
B	385	18.5	14.9	16.0	12.0	19.0	8.0	57.0

Baseline Liver Function Test Results: Aspartate Amino Transferase (IU/L)

See Figure LABB–1 on page 25.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	20.9	10.2	19.0	16.0	23.0	11.0	33.0
B	385	20.9	11.3	19.0	15.0	23.0	11.0	54.0

Baseline Liver Function Test Results: Total Bilirubin (IU/L)

See Figure LABB–1 on page 25.

Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95
A	388	8.3	6.8	7.0	5.0	10.0	2.0	16.0
B	385	7.7	4.3	7.0	5.0	9.0	2.0	13.0

Chapter 3

Adverse Events

3.1 Serious Adverse Events

Table Set SAE–1

Serious Adverse Events: Overview

See Figure SAE–1 on page 27.

			Value					
			Yes		No			P-
	Trt	Total Subjs	N	%	N	%	Contrast	Value
Any SAE	A	388	108	27.84	280	72.16	A.B	0.855
	B	387	110	28.42	277	71.58		
Multiple SAEs	A	388	38	9.79	350	90.21	A.B	0.459
	B	387	32	8.27	355	91.73		
Fatal SAE	A	388	47	12.11	341	87.89	A.B	0.022
	B	387	28	7.24	359	92.76		

Serious Adverse Events: First Serious Adverse Event Probability over Time

See Figure SAE–1 on page 27.

Weeks	Trt	nRisk	nEvents	% w/ Event	95% CI
0	A	388	0	0.3	(0.0, 0.8)
	B	387	0	0.8	(0.0, 1.6)
3	A	380	10	2.6	(1.0, 4.1)
	B	378	14	3.6	(1.7, 5.5)
6	A	372	18	4.6	(2.5, 6.7)
	B	365	25	6.5	(4.0, 8.9)
9	A	364	27	7.0	(4.4, 9.5)
	B	357	32	8.3	(5.5, 11.0)
12	A	356	34	8.8	(5.9, 11.5)
	B	348	40	10.3	(7.3, 13.3)
15	A	348	40	10.3	(7.2, 13.3)
	B	343	46	11.9	(8.6, 15.1)
18	A	341	47	12.1	(8.8, 15.3)
	B	329	56	14.5	(10.9, 18.0)

(Continued on next page.)

(Continued from previous page.)

Serious Adverse Events: First Serious Adverse Event Probability over Time

See Figure SAE–1 on page 27.

Weeks	Trt	nRisk	nEvents	% w/ Event	95% CI
21	A	324	55	14.3	(10.7, 17.7)
	B	317	63	16.4	(12.6, 20.0)
24	A	305	66	17.3	(13.4, 21.0)
	B	301	72	18.8	(14.8, 22.6)
27	A	283	75	19.8	(15.7, 23.8)
	B	276	84	22.1	(17.8, 26.2)
30	A	263	80	21.3	(17.0, 25.4)
	B	253	90	23.9	(19.5, 28.1)
33	A	238	82	22.0	(17.6, 26.1)
	B	224	95	25.5	(20.9, 29.8)
36	A	202	87	23.7	(19.2, 28.0)
	B	192	100	27.3	(22.5, 31.8)
39	A	166	98	28.3	(23.2, 33.0)
	B	165	100	27.3	(22.5, 31.8)
42	A	126	100	29.3	(24.1, 34.1)
	B	132	103	28.8	(23.8, 33.5)
45	A	83	103	31.6	(25.9, 36.9)
	B	87	107	31.4	(25.9, 36.5)
48	A	52	105	33.8	(27.4, 39.7)
	B	61	109	33.4	(27.3, 39.0)
51	A	32	107	36.9	(29.3, 43.7)
	B	40	110	35.1	(28.2, 41.3)
54	A	21	108	39.1	(30.4, 46.7)
	B	28	110	35.1	(28.2, 41.3)
57	A	11	108	39.1	(30.4, 46.7)
	B	14	110	35.1	(28.2, 41.3)
60	A	7	108	39.1	(30.4, 46.7)
	B	9	110	35.1	(28.2, 41.3)
63	A	4	108	39.1	(30.4, 46.7)
	B	4	110	35.1	(28.2, 41.3)
66	A	1	108	39.1	(30.4, 46.7)
	B	2	110	35.1	(28.2, 41.3)

Table Set SAE–2

SAEs by System Organ Class: System Organ Class

See Figure SAE–2 on page 28.

			Value					
		Total	Yes		No			P-
	Trt	Subjs	N	%	N	%	Contrast	Value
Blood, lymphatic	A	388	12	3.09	376	96.91	A.B	0.834
	B	387	13	3.36	374	96.64		

(Continued on next page.)

(Continued from previous page.)

SAEs by System Organ Class: System Organ Class

See Figure SAE–2 on page 28.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Cardiac	A	388	30	7.73	358	92.27	A.B	0.793
	B	387	28	7.24	359	92.76		
Congenital, familial, genetic	A	388	5	1.29	383	98.71	A.B	0.740
	B	387	4	1.03	383	98.97		
Ear, labyrinth	A	388	9	2.32	379	97.68	A.B	0.082
	B	387	3	0.78	384	99.22		
Endocrine	A	388	6	1.55	382	98.45	A.B	0.527
	B	387	4	1.03	383	98.97		
Eye	A	388	6	1.55	382	98.45	A.B	0.765
	B	387	5	1.29	382	98.71		
Gastrointestinal	A	388	4	1.03	384	98.97	A.B	0.001
	B	387	19	4.91	368	95.09		
General, administration site	A	388	3	0.77	385	99.23	A.B	0.997
	B	387	3	0.78	384	99.22		
Hepatobiliary	A	388	9	2.32	379	97.68	A.B	0.812
	B	387	10	2.58	377	97.42		
Immune system	A	388	1	0.26	387	99.74	A.B	0.315
	B	387	3	0.78	384	99.22		
Infections, infestations	A	388	11	2.84	377	97.16	A.B	0.131
	B	387	5	1.29	382	98.71		
Injury, poisoning, procedural	A	388	10	2.58	378	97.42	A.B	0.820
	B	387	11	2.84	376	97.16		
Investigations	A	388	6	1.55	382	98.45	A.B	0.069
	B	387	14	3.62	373	96.38		
Metabolism, nutrition	A	388	2	0.52	386	99.48	A.B	0.564
	B	387	1	0.26	386	99.74		

SAEs by System Organ Class: System Organ Class

See Figure SAE–2 on page 28.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Musculoskeletal, connective tissue	A	388	4	1.03	384	98.97	A.B	0.179
	B	387	1	0.26	386	99.74		
Neoplasms	A	388	11	2.84	377	97.16	A.B	0.343
	B	387	7	1.81	380	98.19		
Nervous system	A	388	3	0.77	385	99.23	A.B	0.317
	B	387	1	0.26	386	99.74		
Pregnancy	A	388	2	0.52	386	99.48	A.B	0.564
	B	387	1	0.26	386	99.74		
Psychiatric	A	388	8	2.06	380	97.94	A.B	0.096
	B	387	16	4.13	371	95.87		

(Continued on next page.)

(Continued from previous page.)

SAEs by System Organ Class: System Organ Class

See Figure SAE–2 on page 28.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Renal, urinary	A	388	1	0.26	387	99.74	A.B	0.057
	B	387	6	1.55	381	98.45		
Reproductive, breast	A	388	10	2.58	378	97.42	A.B	0.821
	B	387	9	2.33	378	97.67		
Respiratory, thoracic, mediastinal	A	388	13	3.35	375	96.65	A.B	0.530
	B	387	10	2.58	377	97.42		
Skin, subcutaneous tissue	A	388	13	3.35	375	96.65	A.B	0.995
	B	387	13	3.36	374	96.64		
Social circumstances	A	388	21	5.41	367	94.59	A.B	0.404
	B	387	16	4.13	371	95.87		
Surgical, medical procedures	A	388	12	3.09	376	96.91	A.B	0.834
	B	387	13	3.36	374	96.64		
Vascular	A	388	6	1.55	382	98.45	A.B	0.058
	B	387	1	0.26	386	99.74		
– Uncoded –	A	388	0	0.00	388	100.00	A.B	1.000
	B	387	0	0.00	387	100.00		

3.2 Adverse Events

Table Set AE–1

Adverse Events: Overview

See Figure AE–1 on page 30.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Any AE	A	388	186	47.94	202	52.06	A.B	0.495
	B	387	195	50.39	192	49.61		
AE related to investigational product	A	388	68	17.53	320	82.47	A.B	0.121
	B	387	85	21.96	302	78.04		

Adverse Events: Actions Taken with IP Due to Any AE

See Figure AE–1 on page 30.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
IP withdrawn	A	388	61	15.72	327	84.28	A.B	0.380
	B	387	70	18.09	317	81.91		
Dose reduced	A	388	91	23.45	297	76.55	A.B	0.491
	B	387	99	25.58	288	74.42		
Dose increased	A	388	3	0.77	385	99.23	A.B	0.997
	B	387	3	0.78	384	99.22		

(Continued on next page.)

(Continued from previous page.)

Adverse Events: Actions Taken with IP Due to Any AE

See Figure AE–1 on page 30.

			Value					
		Total	Yes		No			P-
	Trt	Subjs	N	%	N	%	Contrast	Value
Dose unchanged	A	388	112	28.87	276	71.13	A.B	0.345
	B	387	100	25.84	287	74.16		
Dose interrupted	A	388	38	9.79	350	90.21	A.B	0.721
	B	387	35	9.04	352	90.96		

Adverse Events: Subject Actions Taken Due to Any AE

See Figure AE–1 on page 30.

		Value					
	Total	Withdrawn from study		Not withdrawn from study			P-
Trt	Subjs	N	%	N	%	Contrast	Value
A	388	5	1.29	383	98.71	A.B	0.036
B	387	14	3.62	373	96.38		

Table Set AE–2

AEs by System Organ Class and Severity: System Organ Class

See Figure AE–2 on page 31.

			Value									
		Total	Severe		Moderate		Mild		None			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
*** OVERALL ***	A	388	22	5.67	27	6.96	137	35.31	202	52.06	A.B	0.676
	B	387	14	3.62	32	8.27	149	38.50	192	49.61		
Blood, lymphatic	A	388	3	0.77	1	0.26	22	5.67	362	93.30	A.B	0.206
	B	387	6	1.55	6	1.55	23	5.94	352	90.96		
Cardiac	A	388	11	2.84	10	2.58	68	17.53	299	77.06	A.B	0.117
	B	387	8	2.07	14	3.62	48	12.40	317	81.91		
Congenital, familial, genetic	A	388	1	0.26	3	0.77	11	2.84	373	96.13	A.B	0.475
	B	387	1	0.26	5	1.29	13	3.36	368	95.09		
Ear, labyrinth	A	388	4	1.03	2	0.52	7	1.80	375	96.65	A.B	0.102
	B	387	0	0.00	1	0.26	5	1.29	381	98.45		
Endocrine	A	388	1	0.26	2	0.52	8	2.06	377	97.16	A.B	0.659
	B	387	2	0.52	1	0.26	6	1.55	378	97.67		
Eye	A	388	1	0.26	4	1.03	8	2.06	375	96.65	A.B	0.714
	B	387	0	0.00	2	0.52	13	3.36	372	96.12		
Gastrointestinal	A	388	2	0.52	1	0.26	13	3.35	372	95.88	A.B	0.000
	B	387	5	1.29	7	1.81	39	10.08	336	86.82		
General, administration site	A	388	1	0.26	1	0.26	4	1.03	382	98.45	A.B	0.218
	B	387	1	0.26	3	0.78	7	1.81	376	97.16		
Hepatobiliary	A	388	5	1.29	5	1.29	14	3.61	364	93.81	A.B	0.582
	B	387	4	1.03	4	1.03	20	5.17	359	92.76		
Immune system	A	388	0	0.00	2	0.52	5	1.29	381	98.20	A.B	0.452
	B	387	2	0.52	3	0.78	5	1.29	377	97.42		

(Continued on next page.)

(Continued from previous page.)

AEs by System Organ Class and Severity: System Organ Class

See Figure AE–2 on page 31.

			Value									
		Total	Severe		Moderate		Mild		None			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
Infections, infestations	A	388	1	0.26	5	1.29	17	4.38	365	94.07	A.B	0.905
	B	387	3	0.78	5	1.29	14	3.62	365	94.32		
Injury, poisoning, procedural	A	388	3	0.77	4	1.03	11	2.84	370	95.36	A.B	0.621
	B	387	4	1.03	3	0.78	14	3.62	366	94.57		
Investigations	A	388	1	0.26	1	0.26	21	5.41	365	94.07	A.B	0.087
	B	387	5	1.29	6	1.55	24	6.20	352	90.96		

AEs by System Organ Class and Severity: System Organ Class

See Figure AE–2 on page 31.

			Value									
		Total	Severe		Moderate		Mild		None			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
Metabolism, nutrition	A	388	0	0.00	0	0.00	3	0.77	385	99.23	A.B	0.656
	B	387	0	0.00	0	0.00	2	0.52	385	99.48		
Musculoskeletal, connective tissue	A	388	1	0.26	3	0.77	4	1.03	380	97.94	A.B	0.797
	B	387	1	0.26	2	0.52	4	1.03	380	98.19		
Neoplasms	A	388	5	1.29	1	0.26	16	4.12	366	94.33	A.B	0.637
	B	387	2	0.52	4	1.03	13	3.36	368	95.09		
Nervous system	A	388	0	0.00	1	0.26	3	0.77	384	98.97	A.B	0.730
	B	387	0	0.00	3	0.78	2	0.52	382	98.71		
Pregnancy	A	388	0	0.00	0	0.00	2	0.52	386	99.48	A.B	0.408
	B	387	1	0.26	1	0.26	2	0.52	383	98.97		
Psychiatric	A	388	3	0.77	2	0.52	22	5.67	361	93.04	A.B	0.088
	B	387	4	1.03	8	2.07	28	7.24	347	89.66		
Renal, urinary	A	388	1	0.26	0	0.00	8	2.06	379	97.68	A.B	0.814
	B	387	0	0.00	2	0.52	6	1.55	379	97.93		
Reproductive, breast	A	388	1	0.26	2	0.52	17	4.38	368	94.85	A.B	0.440
	B	387	2	0.52	1	0.26	22	5.68	362	93.54		
Respiratory, thoracic, mediastinal	A	388	4	1.03	2	0.52	22	5.67	360	92.78	A.B	0.999
	B	387	3	0.78	2	0.52	23	5.94	359	92.76		
Skin, subcutaneous tissue	A	388	4	1.03	4	1.03	32	8.25	348	89.69	A.B	0.740
	B	387	3	0.78	6	1.55	28	7.24	350	90.44		
Social circumstances	A	388	9	2.32	4	1.03	36	9.28	339	87.37	A.B	0.446
	B	387	1	0.26	3	0.78	39	10.08	344	88.89		
Surgical, medical procedures	A	388	1	0.26	4	1.03	34	8.76	349	89.95	A.B	0.605
	B	387	4	1.03	7	1.81	23	5.94	353	91.21		
Vascular	A	388	2	0.52	4	1.03	10	2.58	372	95.88	A.B	0.429
	B	387	0	0.00	1	0.26	11	2.84	375	96.90		
– Uncoded –	A	388	1	0.26	0	0.00	0	0.00	387	99.74	A.B	1.000
	B	387	0	0.00	0	0.00	1	0.26	386	99.74		

Table Set AE–3

Most Common AEs by Preferred Term: Preferred Term

See Figure AE–3 on page 32.

			Value									
		Total	Severe		Moderate		Mild		None			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
Chronic obstructive airway	A	388	15	3.87	21	5.41	110	28.35	242	62.37	A.B	0.000
	B	387	6	1.55	13	3.36	62	16.02	306	79.07		
Diarrhoea	A	388	3	0.77	6	1.55	32	8.25	347	89.43	A.B	0.000
	B	387	6	1.55	16	4.13	54	13.95	311	80.36		
Nausea	A	388	3	0.77	3	0.77	17	4.38	365	94.07	A.B	0.000
	B	387	10	2.58	12	3.10	49	12.66	316	81.65		
Upper respiratory tract infection	A	388	9	2.32	13	3.35	39	10.05	327	84.28	A.B	0.414
	B	387	5	1.29	18	4.65	47	12.14	317	81.91		
Abdominal pain	A	388	4	1.03	6	1.55	21	5.41	357	92.01	A.B	0.001
	B	387	5	1.29	12	3.10	43	11.11	327	84.50		
Dyspepsia	A	388	1	0.26	2	0.52	14	3.61	371	95.62	A.B	0.001
	B	387	3	0.78	9	2.33	29	7.49	346	89.41		
Headache	A	388	2	0.52	8	2.06	18	4.64	360	92.78	A.B	0.877
	B	387	2	0.52	5	1.29	20	5.17	360	93.02		
Vomiting	A	388	1	0.26	5	1.29	16	4.12	366	94.33	A.B	0.006
	B	387	3	0.78	11	2.84	29	7.49	344	88.89		
Sinusitis	A	388	3	0.77	5	1.29	20	5.15	360	92.78	A.B	0.713
	B	387	1	0.26	3	0.78	27	6.98	356	91.99		
Injury	A	388	1	0.26	1	0.26	21	5.41	365	94.07	A.B	0.419
	B	387	7	1.81	4	1.03	17	4.39	359	92.76		
Infection viral	A	388	4	1.03	7	1.80	25	6.44	352	90.72	A.B	0.323
	B	387	5	1.29	7	1.81	16	4.13	359	92.76		
Dizziness	A	388	1	0.26	0	0.00	15	3.87	372	95.88	A.B	0.371
	B	387	3	0.78	5	1.29	13	3.36	366	94.57		
Coughing	A	388	5	1.29	3	0.77	14	3.61	366	94.33	A.B	0.622
	B	387	2	0.52	3	0.78	14	3.62	368	95.09		
Insomnia	A	388	1	0.26	0	0.00	5	1.29	382	98.45	A.B	0.000
	B	387	6	1.55	8	2.07	20	5.17	353	91.21		
Back pain	A	388	3	0.77	4	1.03	16	4.12	365	94.07	A.B	0.241
	B	387	0	0.00	2	0.52	14	3.62	371	95.87		

Most Common AEs by Preferred Term: Preferred Term

See Figure AE–3 on page 32.

			Value									
		Total	Severe		Moderate		Mild		None			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
Rhinitis	A	388	5	1.29	2	0.52	14	3.61	367	94.59	A.B	0.161
	B	387	2	0.52	2	0.52	9	2.33	374	96.64		
Flatulence	A	388	0	0.00	1	0.26	5	1.29	382	98.45	A.B	0.001
	B	387	1	0.26	2	0.52	20	5.17	364	94.06		
Dyspnoea	A	388	2	0.52	2	0.52	17	4.38	367	94.59	A.B	0.003
	B	387	0	0.00	1	0.26	5	1.29	381	98.45		
Chest pain	A	388	1	0.26	4	1.03	14	3.61	369	95.10	A.B	0.032
	B	387	0	0.00	3	0.78	5	1.29	379	97.93		
Bronchitis	A	388	3	0.77	2	0.52	10	2.58	373	96.13	A.B	0.551
	B	387	1	0.26	1	0.26	10	2.58	375	96.90		
Respiratory disorder	A	388	0	0.00	2	0.52	15	3.87	371	95.62	A.B	0.873
	B	387	2	0.52	1	0.26	13	3.36	371	95.87		
Anorexia	A	388	0	0.00	1	0.26	7	1.80	380	97.94	A.B	0.046
	B	387	1	0.26	0	0.00	17	4.39	369	95.35		
Pain	A	388	0	0.00	1	0.26	10	2.58	377	97.16	A.B	0.317
	B	387	1	0.26	3	0.78	12	3.10	371	95.87		
Fatigue	A	388	2	0.52	1	0.26	6	1.55	379	97.68	A.B	0.649
	B	387	0	0.00	4	1.03	7	1.81	376	97.16		
Gastroesophageal reflux	A	388	1	0.26	4	1.03	5	1.29	378	97.42	A.B	0.659
	B	387	2	0.52	4	1.03	6	1.55	375	96.90		
Flash	A	388	1	0.26	3	0.77	8	2.06	376	96.91	A.B	0.249
	B	387	2	0.52	0	0.00	5	1.29	380	98.19		
Hyperkalemia	A	388	1	0.26	3	0.77	5	1.29	379	97.68	A.B	0.810
	B	387	3	0.78	1	0.26	6	1.55	377	97.42		
Melena	A	388	2	0.52	3	0.77	5	1.29	378	97.42	A.B	0.534
	B	387	1	0.26	2	0.52	10	2.58	374	96.64		
Urinary tract infection	A	388	0	0.00	2	0.52	9	2.32	377	97.16	A.B	0.831
	B	387	0	0.00	2	0.52	8	2.07	377	97.42		
Myalgia	A	388	1	0.26	3	0.77	7	1.80	377	97.16	A.B	0.673
	B	387	1	0.26	4	1.03	8	2.07	374	96.64		

Chapter 4

Central Laboratory Measures

4.1 Liver Function Tests

Table Set LFTABN–1

Summary of Liver Function Test Elevations: Highest Elevation after Baseline

See Figure LFTABN–1 on page 36.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Alkaline Phosphatase	Total Subjs	358		363		A.B	0.045
	>3 xULN	2	0.56	1	0.28		
	>2-3 xULN	4	1.12	11	3.03		
	>1-2 xULN	47	13.13	62	17.08		
	≤ ULN	305	85.20	289	79.61		
Alanine Aminotransferase	Total Subjs	358		363		A.B	0.178
	>3 xULN	0	0.00	1	0.28		
	>2-3 xULN	0	0.00	8	2.20		
	>1-2 xULN	34	9.50	36	9.92		
	≤ ULN	324	90.50	318	87.60		
Aspartate Aminotransferase	Total Subjs	358		363		A.B	0.380
	>3 xULN	1	0.28	4	1.10		
	>2-3 xULN	3	0.84	5	1.38		
	>1-2 xULN	38	10.61	41	11.29		
	≤ ULN	316	88.27	313	86.23		
Total Bilirubin	Total Subjs	358		363		A.B	0.642
	>3 xULN	1	0.28	3	0.83		
	>2-3 xULN	3	0.84	2	0.55		
	>1-2 xULN	27	7.54	30	8.26		
	≤ ULN	327	91.34	328	90.36		

Table Set LFT–1

Alkaline Phosphatase: Measurements at Scheduled Visits (IU/L)

See Figure LFT–1 on page 37.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	79.3	36.6	74.0	63.0	85.0	45.0	114.0	A.B	0.876
	B	385	77.8	28.5	73.0	63.0	85.0	49.0	132.0		
Month 3	A	358	81.1	31.6	75.0	62.0	90.0	48.0	157.0	A.B	0.000
	B	363	91.2	41.7	83.0	71.0	99.0	51.0	165.0		
Month 6	A	300	82.3	38.2	77.0	66.0	89.5	45.5	145.5	A.B	0.000
	B	312	91.2	36.6	85.0	72.0	99.0	56.0	165.0		
Month 9	A	168	82.7	29.3	79.0	65.0	91.0	49.0	147.0	A.B	0.003
	B	173	91.7	37.2	86.0	71.0	100.0	53.0	171.0		
Month 12	A	35	81.6	23.1	81.0	65.0	89.0	51.0	119.0	A.B	0.016
	B	35	102.7	57.2	93.0	77.0	107.0	47.0	306.0		

Alkaline Phosphatase: Above Upper Limit of Normal (125 IU/L)

See Figure LFT–1 on page 37.

			Value									
		Total	>3 xULN		>2-3 xULN		>1-2 xULN		≤ ULN			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
Baseline	A	388	1	0.26	5	1.29	13	3.35	369	95.10	A.B	0.749
	B	385	0	0.00	3	0.78	18	4.68	364	94.55		
Month 3	A	358	0	0.00	2	0.56	25	6.98	331	92.46	A.B	0.303
	B	363	1	0.28	4	1.10	30	8.26	328	90.36		
Month 6	A	300	2	0.67	1	0.33	14	4.67	283	94.33	A.B	0.203
	B	312	0	0.00	3	0.96	23	7.37	286	91.67		
Month 9	A	168	0	0.00	1	0.60	9	5.36	158	94.05	A.B	0.436
	B	173	0	0.00	2	1.16	12	6.94	159	91.91		
Month 12	A	35	0	0.00	0	0.00	1	2.86	34	97.14	A.B	0.293
	B	35	0	0.00	2	5.71	1	2.86	32	91.43		

Alkaline Phosphatase: Absolute Change from Baseline (IU/L)

See Figure LFT–1 on page 37.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	358	1.3	47.9	1.5	-14.0	19.0	-49.0	78.0	A.B	0.000
	B	362	13.4	51.5	11.5	-8.0	30.0	-56.0	91.0		
Month 6	A	300	3.4	53.0	2.0	-15.5	22.5	-48.0	65.0	A.B	0.000
	B	311	14.5	43.9	12.0	-8.0	31.0	-40.0	93.0		
Month 9	A	168	5.4	40.9	5.0	-13.0	23.5	-48.0	70.0	A.B	0.073
	B	172	12.2	50.8	12.5	-8.0	35.0	-67.0	97.0		
Month 12	A	35	10.2	28.5	6.0	-10.0	28.0	-30.0	58.0	A.B	0.401
	B	35	18.2	65.9	20.0	-12.0	40.0	-94.0	214.0		

Table Set LFT–2

Alanine Amino Transferase: Measurements at Scheduled Visits (IU/L)

See Figure LFT–2 on page 38.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	16.9	10.5	15.0	12.0	19.0	7.0	26.0	A.B	0.290
	B	385	18.5	14.9	16.0	12.0	19.0	8.0	57.0		
Month 3	A	358	17.8	10.2	16.0	13.0	20.0	7.0	28.0	A.B	0.001
	B	363	21.6	18.0	18.0	14.0	23.0	9.0	67.0		
Month 6	A	300	18.7	11.3	17.0	13.0	21.0	7.5	46.0	A.B	0.000
	B	312	21.4	16.3	19.0	14.0	23.0	8.0	66.0		
Month 9	A	168	17.4	10.3	15.0	12.0	20.0	7.0	27.0	A.B	0.001
	B	173	20.6	14.4	18.0	14.0	22.0	8.0	64.0		
Month 12	A	35	17.6	9.4	16.0	12.0	20.0	10.0	27.0	A.B	0.122
	B	35	18.7	6.2	20.0	15.0	24.0	8.0	29.0		

Alanine Amino Transferase: Above Upper Limit of Normal (48 IU/L)

See Figure LFT–2 on page 38.

			Value									
		Total	>3 xULN		>2-3 xULN		>1-2 xULN		≤ ULN			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
Baseline	A	388	0	0.00	1	0.26	14	3.61	373	96.13	A.B	0.132
	B	385	2	0.52	0	0.00	22	5.71	361	93.77		
Month 3	A	358	0	0.00	0	0.00	14	3.91	344	96.09	A.B	0.130
	B	363	0	0.00	6	1.65	17	4.68	340	93.66		
Month 6	A	300	0	0.00	0	0.00	15	5.00	285	95.00	A.B	0.790
	B	312	1	0.32	1	0.32	15	4.81	295	94.55		
Month 9	A	168	0	0.00	0	0.00	6	3.57	162	96.43	A.B	0.458
	B	173	0	0.00	1	0.58	8	4.62	164	94.80		
Month 12	A	35	0	0.00	0	0.00	1	2.86	34	97.14	A.B	0.317
	B	35	0	0.00	0	0.00	0	0.00	35	100.00		

Alanine Amino Transferase: Absolute Change from Baseline (IU/L)

See Figure LFT–2 on page 38.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	358	1.0	14.8	2.0	-4.0	7.0	-16.0	16.0	A.B	0.265
	B	362	3.1	23.3	2.0	-4.0	9.0	-35.0	47.0		
Month 6	A	300	1.4	16.1	1.0	-4.0	6.0	-17.5	31.0	A.B	0.023
	B	311	2.8	21.6	3.0	-2.0	8.0	-32.0	26.0		
Month 9	A	168	0.0	15.1	0.0	-5.0	6.0	-38.0	17.0	A.B	0.019
	B	172	3.0	18.2	3.0	-3.0	9.0	-39.0	21.0		
Month 12	A	35	-1.9	19.0	1.0	-5.0	8.0	-47.0	13.0	A.B	0.188
	B	35	0.1	16.6	4.0	-2.0	11.0	-37.0	17.0		

Table Set LFT–3

Aspartate Amino Transferase: Measurements at Scheduled Visits (IU/L)

See Figure LFT–3 on page 39.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	20.9	10.2	19.0	16.0	23.0	11.0	33.0	A.B	0.174
	B	385	20.9	11.3	19.0	15.0	23.0	11.0	54.0		
Month 3	A	358	21.7	9.5	20.0	17.0	23.0	11.0	31.0	A.B	0.000
	B	363	24.6	14.3	22.0	18.0	26.0	12.0	59.0		
Month 6	A	300	22.0	14.1	20.0	16.0	23.0	12.0	41.5	A.B	0.001
	B	312	24.1	17.3	21.0	18.0	26.0	12.0	35.0		
Month 9	A	168	21.6	10.7	20.0	16.0	24.0	12.0	33.0	A.B	0.010
	B	173	25.3	18.4	21.0	18.0	26.0	12.0	60.0		
Month 12	A	35	26.8	21.2	21.0	17.0	24.0	13.0	68.0	A.B	0.480
	B	35	23.8	12.3	21.0	17.0	26.0	12.0	65.0		

Aspartate Amino Transferase: Above Upper Limit of Normal (42-55 IU/L)

See Figure LFT–3 on page 39.

			Value									
		Total	>3 xULN		>2-3 xULN		>1-2 xULN		≤ ULN			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
Baseline	A	388	0	0.00	1	0.26	15	3.87	372	95.88	A.B	0.187
	B	385	0	0.00	1	0.26	23	5.97	361	93.77		
Month 3	A	358	0	0.00	0	0.00	16	4.47	342	95.53	A.B	0.328
	B	363	1	0.28	2	0.55	19	5.23	341	93.94		
Month 6	A	300	1	0.33	1	0.33	13	4.33	285	95.00	A.B	0.927
	B	312	2	0.64	2	0.64	11	3.53	297	95.19		
Month 9	A	168	0	0.00	1	0.60	6	3.57	161	95.83	A.B	0.188
	B	173	1	0.58	1	0.58	11	6.36	160	92.49		
Month 12	A	35	0	0.00	1	2.86	4	11.43	30	85.71	A.B	0.227
	B	35	0	0.00	0	0.00	2	5.71	33	94.29		

Aspartate Amino Transferase: Absolute Change from Baseline (IU/L)

See Figure LFT–3 on page 39.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	358	0.6	14.3	1.0	-5.0	6.0	-18.0	16.0	A.B	0.000
	B	362	3.7	17.7	3.0	-3.0	9.0	-18.0	25.0		
Month 6	A	300	0.7	17.4	0.0	-5.0	5.0	-19.0	25.5	A.B	0.000
	B	311	3.6	20.1	3.0	-4.0	10.0	-29.0	21.0		
Month 9	A	168	0.2	15.7	1.0	-5.0	5.0	-17.0	18.0	A.B	0.002
	B	172	5.1	20.8	3.5	-3.0	8.5	-27.0	47.0		
Month 12	A	35	8.0	20.5	1.0	-4.0	9.0	-7.0	44.0	A.B	0.967
	B	35	1.9	15.1	2.0	-3.0	10.0	-40.0	18.0		

Table Set LFT–4

Total Bilirubin: Measurements at Scheduled Visits (IU/L)

See Figure LFT–4 on page 40.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	8.3	6.8	7.0	5.0	10.0	2.0	16.0	A.B	0.896
	B	385	7.7	4.3	7.0	5.0	9.0	2.0	13.0		
Month 3	A	358	8.0	5.1	8.0	5.0	10.0	2.0	13.0	A.B	0.591
	B	363	8.5	6.9	8.0	5.0	10.0	2.0	15.0		
Month 6	A	300	8.4	7.0	7.0	5.0	9.0	3.0	20.5	A.B	0.037
	B	312	8.6	5.3	8.0	6.0	10.0	2.0	16.0		
Month 9	A	168	7.3	4.1	7.0	5.0	9.0	3.0	12.0	A.B	0.002
	B	173	9.2	8.8	8.0	6.0	10.0	3.0	17.0		
Month 12	A	35	7.8	3.1	8.0	6.0	10.0	3.0	13.0	A.B	0.255
	B	35	9.7	6.0	8.0	6.0	11.0	3.0	29.0		

Total Bilirubin: Above Upper Limit of Normal (22 IU/L)

See Figure LFT–4 on page 40.

			Value									
		Total	>3 xULN		>2-3 xULN		>1-2 xULN		≤ ULN			P-
	Trt	Subjs	N	%	N	%	N	%	N	%	Contrast	Value
Baseline	A	388	1	0.26	3	0.77	15	3.87	369	95.10	A.B	0.089
	B	385	0	0.00	0	0.00	10	2.60	375	97.40		
Month 3	A	358	0	0.00	1	0.28	11	3.07	346	96.65	A.B	0.856
	B	363	1	0.28	2	0.55	10	2.75	350	96.42		
Month 6	A	300	1	0.33	2	0.67	12	4.00	285	95.00	A.B	0.605
	B	312	0	0.00	0	0.00	13	4.17	299	95.83		
Month 9	A	168	0	0.00	0	0.00	4	2.38	164	97.62	A.B	0.256
	B	173	2	1.16	0	0.00	6	3.47	165	95.38		
Month 12	A	35	0	0.00	0	0.00	0	0.00	35	100.00	A.B	0.154
	B	35	0	0.00	0	0.00	2	5.71	33	94.29		

Total Bilirubin: Absolute Change from Baseline (IU/L)

See Figure LFT–4 on page 40.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	358	-0.3	8.4	0.0	-4.0	4.0	-16.0	9.0	A.B	0.489
	B	362	0.9	7.9	0.0	-3.0	4.0	-9.0	10.0		
Month 6	A	300	0.1	9.8	0.0	-4.0	3.0	-13.5	12.5	A.B	0.093
	B	311	1.0	6.7	0.0	-3.0	4.0	-8.0	11.0		
Month 9	A	168	-1.1	7.7	-0.5	-3.0	3.0	-17.0	8.0	A.B	0.018
	B	172	1.4	9.0	1.0	-3.0	4.0	-9.0	12.0		
Month 12	A	35	-1.5	5.7	0.0	-4.0	2.0	-19.0	4.0	A.B	0.189
	B	35	0.8	9.2	1.0	-3.0	5.0	-17.0	21.0		

4.2 Clinical Chemistry

Table Set CHEMABN–1

Summary of Abnormal Clinical Chemistry Values: Ever Below LLN

See Figure CHEMABN–1 on page 41.

			Value					
		Total	Yes		No			P-
	Trt	Subjs	N	%	N	%	Contrast	Value
LDL Cholesterol	A	358	0	0.00	358	100.00	A.B	1.000
	B	363	0	0.00	363	100.00		
HDL Cholesterol	A	358	189	52.79	169	47.21	A.B	0.623
	B	363	185	50.96	178	49.04		
Total Cholesterol	A	358	0	0.00	358	100.00	A.B	1.000
	B	363	0	0.00	363	100.00		
Triglycerides	A	358	0	0.00	358	100.00	A.B	1.000
	B	363	0	0.00	363	100.00		
Sodium	A	388	17	4.38	371	95.62	A.B	0.119
	B	387	27	6.98	360	93.02		
Potassium	A	388	7	1.80	381	98.20	A.B	0.120
	B	387	14	3.62	373	96.38		
Chloride	A	388	10	2.58	378	97.42	A.B	0.465
	B	387	7	1.81	380	98.19		
Bicarbonate	A	388	53	13.66	335	86.34	A.B	0.092
	B	387	70	18.09	317	81.91		
Blood Urea Nitrogen	A	388	0	0.00	388	100.00	A.B	1.000
	B	387	0	0.00	387	100.00		
Creatinine	A	388	0	0.00	388	100.00	A.B	0.082
	B	387	3	0.78	384	99.22		
Glucose	A	388	13	3.35	375	96.65	A.B	0.530
	B	387	10	2.58	377	97.42		
Calcium	A	388	14	3.61	374	96.39	A.B	0.994
	B	387	14	3.62	373	96.38		

Summary of Abnormal Clinical Chemistry Values: Ever Above ULN

See Figure CHEMABN–1 on page 41.

			Value					
		Total	Yes		No			P-
	Trt	Subjs	N	%	N	%	Contrast	Value
LDL Cholesterol	A	358	123	34.36	235	65.64	A.B	0.121
	B	363	145	39.94	218	60.06		
HDL Cholesterol	A	358	0	0.00	358	100.00	A.B	1.000
	B	363	0	0.00	363	100.00		
Total Cholesterol	A	358	133	37.15	225	62.85	A.B	0.284
	B	363	149	41.05	214	58.95		
Triglycerides	A	358	211	58.94	147	41.06	A.B	0.818
	B	363	217	59.78	146	40.22		

(Continued on next page.)

(Continued from previous page.)

Summary of Abnormal Clinical Chemistry Values: Ever Above ULN

See Figure CHEMABN–1 on page 41.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Sodium	A	388	35	9.02	353	90.98	A.B	0.461
	B	387	41	10.59	346	89.41		
Potassium	A	388	74	19.07	314	80.93	A.B	0.107
	B	387	57	14.73	330	85.27		
Chloride	A	388	29	7.47	359	92.53	A.B	0.298
	B	387	37	9.56	350	90.44		
Bicarbonate	A	388	13	3.35	375	96.65	A.B	0.995
	B	387	13	3.36	374	96.64		
Blood Urea Nitrogen	A	388	204	52.58	184	47.42	A.B	0.064
	B	387	229	59.17	158	40.83		
Creatinine	A	388	54	13.92	334	86.08	A.B	0.078
	B	387	38	9.82	349	90.18		
Glucose	A	388	177	45.62	211	54.38	A.B	0.911
	B	387	175	45.22	212	54.78		
Calcium	A	388	12	3.09	376	96.91	A.B	0.837
	B	387	11	2.84	376	97.16		

Table Set CHEM–1

LDL Cholesterol: Measurements at Scheduled Visits (mmol/L)

See Figure CHEM–1 on page 42.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	2.40	1.12	2.15	1.65	2.88	1.09	4.71	A.B	0.047
	B	385	2.52	1.11	2.34	1.69	3.08	1.17	4.74		
Month 3	A	358	2.38	1.12	2.17	1.63	2.86	1.01	4.55	A.B	0.957
	B	363	2.40	1.14	2.11	1.57	3.03	1.04	4.64		
Month 6	A	300	2.49	1.12	2.32	1.70	3.12	1.05	4.68	A.B	0.731
	B	312	2.57	1.24	2.28	1.65	3.26	1.12	5.03		
Month 9	A	168	2.47	1.03	2.38	1.67	3.05	1.02	4.24	A.B	0.208
	B	173	2.36	0.99	2.12	1.72	2.77	1.21	4.17		
Month 12	A	35	2.37	1.08	2.33	1.52	3.11	0.86	4.47	A.B	0.930
	B	35	2.40	1.22	2.05	1.53	3.03	1.26	4.73		

LDL Cholesterol: Above Upper Limit of Normal (3.35 mmol/L)

See Figure CHEM–1 on page 42.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Baseline	A	388	61	15.72	327	84.28	A.B	0.234
	B	385	73	18.96	312	81.04		
Month 3	A	358	51	14.25	307	85.75	A.B	0.057
	B	363	71	19.56	292	80.44		
Month 6	A	300	52	17.33	248	82.67	A.B	0.114
	B	312	70	22.44	242	77.56		
Month 9	A	168	31	18.45	137	81.55	A.B	0.192
	B	173	23	13.29	150	86.71		
Month 12	A	35	8	22.86	27	77.14	A.B	0.356
	B	35	5	14.29	30	85.71		

LDL Cholesterol: Absolute Change from Baseline (mmol/L)

See Figure CHEM–1 on page 42.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	358	-0.02	1.55	-0.04	-0.91	0.84	-2.62	2.60	A.B	0.347
	B	362	-0.11	1.64	-0.16	-1.05	0.78	-2.66	2.56		
Month 6	A	300	0.08	1.64	0.09	-0.82	1.04	-2.65	2.87	A.B	0.926
	B	311	0.07	1.66	0.13	-0.95	1.06	-2.77	2.52		
Month 9	A	168	0.10	1.50	0.12	-0.70	0.94	-2.50	2.35	A.B	0.022
	B	172	-0.23	1.51	-0.15	-1.03	0.57	-3.35	2.07		
Month 12	A	35	-0.07	1.54	-0.10	-0.97	1.16	-2.69	2.73	A.B	0.967
	B	35	-0.03	1.51	-0.09	-0.69	0.89	-2.58	2.20		

4.3 Hematology

Table Set HEMABN–1

Summary of Abnormal Hematology Values: Ever Below LLN

See Figure HEMABN–1 on page 43.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
White Blood Cells	A	358	63	17.60	295	82.40	A.B	0.273
	B	363	53	14.60	310	85.40		
Red Blood Cells	A	388	152	39.18	236	60.82	A.B	0.678
	B	387	146	37.73	241	62.27		
Hemoglobin	A	388	151	38.92	237	61.08	A.B	0.964
	B	387	150	38.76	237	61.24		
Hematocrit	A	388	178	45.88	210	54.12	A.B	0.859
	B	387	180	46.51	207	53.49		
Mean Corpuscular Volume	A	388	45	11.60	343	88.40	A.B	0.070
	B	387	30	7.75	357	92.25		

(Continued on next page.)

(Continued from previous page.)

Summary of Abnormal Hematology Values: Ever Below LLN

See Figure HEMABN–1 on page 43.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Mean Corpuscular Hemoglobin	A	388	31	7.99	357	92.01	A.B	0.258
	B	387	40	10.34	347	89.66		
Mean Corpuscular Hemoglobin Concentration	A	388	94	24.23	294	75.77	A.B	0.663
	B	387	99	25.58	288	74.42		
Platelets	A	388	60	15.46	328	84.54	A.B	0.775
	B	387	57	14.73	330	85.27		

Summary of Abnormal Hematology Values: Ever Above ULN

See Figure HEMABN–1 on page 43.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
White Blood Cells	A	358	29	8.10	329	91.90	A.B	0.547
	B	363	34	9.37	329	90.63		
Red Blood Cells	A	388	9	2.32	379	97.68	A.B	0.996
	B	387	9	2.33	378	97.67		
Hemoglobin	A	388	4	1.03	384	98.97	A.B	0.707
	B	387	3	0.78	384	99.22		
Hematocrit	A	388	8	2.06	380	97.94	A.B	0.192
	B	387	14	3.62	373	96.38		
Mean Corpuscular Volume	A	388	54	13.92	334	86.08	A.B	0.412
	B	387	62	16.02	325	83.98		
Mean Corpuscular Hemoglobin	A	388	12	3.09	376	96.91	A.B	0.837
	B	387	11	2.84	376	97.16		
Mean Corpuscular Hemoglobin Concentration	A	388	0	0.00	388	100.00	A.B	1.000
	B	387	0	0.00	387	100.00		
Platelets	A	388	7	1.80	381	98.20	A.B	0.996
	B	387	7	1.81	380	98.19		

Table Set HEM–1

White Blood Cell Count: Measurements at Scheduled Visits (x10^9/L)

See Figure HEM–1 on page 44.

		Total		Std							P-
	Trt	Subjs	Mean	Dev	Median	Q1	Q3	P5	P95	Contrast	Value
Baseline	A	388	6.9	2.0	6.7	5.5	8.0	4.1	10.2	A.B	0.811
	B	385	6.9	2.0	6.6	5.4	8.1	4.3	11.0		
Month 3	A	358	7.0	2.1	6.6	5.5	8.2	4.2	10.8	A.B	0.925
	B	363	7.0	2.1	6.9	5.4	8.2	4.1	10.3		
Month 6	A	300	7.0	1.9	6.8	5.5	8.0	4.3	10.3	A.B	0.840
	B	312	7.0	1.9	6.8	5.7	8.2	4.4	10.5		
Month 9	A	168	6.9	1.7	6.7	5.8	7.9	4.4	10.1	A.B	0.975
	B	173	7.0	2.1	6.7	5.7	8.1	4.2	10.7		

(Continued on next page.)

(Continued from previous page.)

White Blood Cell Count: Measurements at Scheduled Visits (x10^9/L)

See Figure HEM–1 on page 44.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 12	A	35	7.1	2.1	6.9	5.5	8.7	4.4	10.8	A.B	0.694
	B	35	6.9	2.0	6.6	5.4	7.8	4.8	9.8		

White Blood Cell Count: Above Upper Limit of Normal (11 x10^9/L)

See Figure HEM–1 on page 44.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Baseline	A	388	14	3.61	374	96.39	A.B	0.362
	B	385	19	4.94	366	95.06		
Month 3	A	358	15	4.19	343	95.81	A.B	0.820
	B	363	14	3.86	349	96.14		
Month 6	A	300	11	3.67	289	96.33	A.B	0.750
	B	312	13	4.17	299	95.83		
Month 9	A	168	2	1.19	166	98.81	A.B	0.165
	B	173	6	3.47	167	96.53		
Month 12	A	35	1	2.86	34	97.14	A.B	1.000
	B	35	1	2.86	34	97.14		

White Blood Cell Count: Below Lower Limit of Normal (4.5 x10^9/L)

See Figure HEM–1 on page 44.

			Value					
			Yes		No			
	Trt	Total Subjs	N	%	N	%	Contrast	P-Value
Baseline	A	388	34	8.76	354	91.24	A.B	0.532
	B	385	29	7.53	356	92.47		
Month 3	A	358	31	8.66	327	91.34	A.B	0.745
	B	363	29	7.99	334	92.01		
Month 6	A	300	20	6.67	280	93.33	A.B	0.898
	B	312	20	6.41	292	93.59		
Month 9	A	168	10	5.95	158	94.05	A.B	0.946
	B	173	10	5.78	163	94.22		
Month 12	A	35	3	8.57	32	91.43	A.B	0.077
	B	35	0	0.00	35	100.00		

White Blood Cell Count: Absolute Change from Baseline (x10^9/L)

See Figure HEM–1 on page 44.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	358	0.05	2.91	0.05	-1.70	1.90	-4.50	4.70	A.B	0.758
	B	362	0.04	3.07	0.00	-1.70	1.90	-4.90	4.80		
Month 6	A	300	0.03	2.79	0.20	-1.70	1.80	-4.55	4.05	A.B	0.961
	B	311	0.08	2.78	0.20	-1.60	1.90	-4.60	4.70		
Month 9	A	168	-0.23	2.56	-0.20	-1.65	1.45	-4.50	3.90	A.B	0.355
	B	172	0.06	3.11	0.10	-1.50	1.85	-5.40	5.20		
Month 12	A	35	0.52	2.71	-0.30	-1.70	2.40	-2.90	5.90	A.B	0.565
	B	35	-0.01	2.87	0.10	-1.40	1.10	-4.40	5.20		

Chapter 5

Other Follow-up and Safety Measures

5.1 Vital Signs

Table Set VIT–1

Systolic Blood Pressure: Measurements at Scheduled Visits (mmHg)

See Figure VIT–1 on page 46.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	123.0	14.4	122.5	111.9	132.2	100.3	147.2	A.B	0.123
	B	386	121.0	15.1	121.5	111.7	130.7	96.2	144.9		
Month 3	A	359	123.2	14.2	123.4	112.8	133.5	100.7	147.1	A.B	0.624
	B	365	122.5	13.8	122.7	113.4	132.6	97.8	144.9		
Month 6	A	300	122.3	14.0	122.3	113.9	131.4	99.1	145.0	A.B	0.285
	B	314	121.2	14.1	120.7	111.3	130.5	97.0	146.0		
Month 9	A	160	123.1	15.3	122.4	112.4	134.0	99.2	148.2	A.B	0.081
	B	170	119.6	14.6	120.6	109.5	130.7	95.6	140.7		
Month 12	A	40	125.1	10.7	123.6	116.9	133.1	106.6	142.3	A.B	0.283
	B	35	121.6	15.8	122.8	111.1	131.7	93.4	147.5		

Systolic Blood Pressure: Elevations (>130 mmHg)

See Figure VIT–1 on page 46.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Baseline	Total Subjs	388		386		A.B	0.335
	>150 mmHg	11	2.84	12	3.11		
	>140-150 mmHg	35	9.02	25	6.48		
	>130-140 mmHg	76	19.59	64	16.58		
Month 3	Total Subjs	359		365		A.B	0.425
	>150 mmHg	10	2.79	6	1.64		
	>140-150 mmHg	31	8.64	37	10.14		
	>130-140 mmHg	76	21.17	65	17.81		

(Continued on next page.)

(Continued from previous page.)

Systolic Blood Pressure: Elevations (>130 mmHg)

See Figure VIT–1 on page 46.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Month 6	Total Subjs	300		314		A.B	0.812
	>150 mmHg	7	2.33	7	2.23		
	>140-150 mmHg	28	9.33	23	7.32		
	>130-140 mmHg	50	16.67	57	18.15		
Month 9	Total Subjs	160		170		A.B	0.149
	>150 mmHg	5	3.12	1	0.59		
	>140-150 mmHg	14	8.75	8	4.71		
	>130-140 mmHg	31	19.38	35	20.59		
Month 12	Total Subjs	40		35		A.B	0.251
	>150 mmHg	0	0.00	1	2.86		
	>140-150 mmHg	3	7.50	4	11.43		
	>130-140 mmHg	11	27.50	4	11.43		

Systolic Blood Pressure: Absolute Change from Baseline (mmHg)

See Figure VIT–1 on page 46.

		Total		Std							P-
	Trt	Subjs	Mean	Dev	Median	Q1	Q3	P5	P95	Contrast	Value
Month 3	A	359	0.1	20.2	0.1	-15.3	13.7	-31.5	32.6	A.B	0.318
	B	364	1.4	20.0	1.3	-11.2	14.9	-30.9	35.7		
Month 6	A	300	-0.2	19.6	0.1	-12.7	12.8	-30.4	31.0	A.B	0.978
	B	313	-0.3	21.0	0.6	-14.2	14.1	-34.6	32.6		
Month 9	A	160	0.0	20.9	1.2	-12.4	15.2	-37.8	32.6	A.B	0.120
	B	170	-2.5	19.3	-3.0	-15.5	9.0	-35.1	30.4		
Month 12	A	40	0.3	17.3	1.1	-12.8	12.1	-28.4	28.9	A.B	0.531
	B	35	-2.4	25.3	3.5	-18.2	11.1	-39.3	47.2		

Systolic Blood Pressure: Increases from Baseline (>6 mmHg)

See Figure VIT–1 on page 46.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Month 3	Total Subjs	359		365		A.B	0.703
	>15 mmHg	84	23.40	90	24.66		
	>10-15 mmHg	28	7.80	24	6.58		
	>6-10 mmHg	23	6.41	30	8.22		
Month 6	Total Subjs	300		314		A.B	0.925
	>15 mmHg	67	22.33	71	22.61		
	>10-15 mmHg	25	8.33	30	9.55		
	>6-10 mmHg	23	7.67	21	6.69		
Month 9	Total Subjs	160		170		A.B	0.251
	>15 mmHg	40	25.00	28	16.47		
	>10-15 mmHg	13	8.12	12	7.06		
	>6-10 mmHg	12	7.50	15	8.82		
Month 12	Total Subjs	40		35		A.B	0.911
	>15 mmHg	8	20.00	7	20.00		
	>10-15 mmHg	4	10.00	2	5.71		
	>6-10 mmHg	5	12.50	4	11.43		

Table Set VIT–2

Diastolic Blood Pressure: Measurements at Scheduled Visits (mmHg)

See Figure VIT–2 on page 47.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	72.0	9.4	71.7	65.3	78.1	57.7	88.6	A.B	0.700
	B	386	72.1	9.8	71.8	66.1	78.4	55.6	88.3		
Month 3	A	359	71.9	9.9	71.4	65.3	79.0	56.0	88.2	A.B	0.808
	B	365	72.1	10.2	72.6	64.8	78.8	55.5	89.3		
Month 6	A	300	71.2	10.3	71.5	65.0	77.9	53.2	88.4	A.B	0.197
	B	314	72.3	9.8	72.2	66.0	78.3	56.5	88.4		
Month 9	A	160	71.7	10.3	71.6	65.7	78.2	55.4	89.7	A.B	0.033
	B	170	74.0	10.1	74.8	67.3	80.9	55.1	89.5		
Month 12	A	40	74.5	10.1	72.9	68.9	80.7	56.8	92.4	A.B	0.129
	B	35	70.5	9.5	70.0	62.0	78.5	55.7	86.3		

Diastolic Blood Pressure: Elevations (>80 mmHg)

See Figure VIT–2 on page 47.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Baseline	Total Subjs	388		386		A.B	0.943
	>90 mmHg	14	3.61	13	3.37		
	>85-90 mmHg	26	6.70	26	6.74		
	>80-85 mmHg	40	10.31	45	11.66		
Month 3	Total Subjs	359		365		A.B	0.670
	>90 mmHg	12	3.34	16	4.38		
	>85-90 mmHg	19	5.29	22	6.03		
	>80-85 mmHg	48	13.37	40	10.96		
Month 6	Total Subjs	300		314		A.B	0.632
	>90 mmHg	12	4.00	12	3.82		
	>85-90 mmHg	12	4.00	19	6.05		
	>80-85 mmHg	40	13.33	36	11.46		
Month 9	Total Subjs	160		170		A.B	0.061
	>90 mmHg	7	4.38	7	4.12		
	>85-90 mmHg	7	4.38	21	12.35		
	>80-85 mmHg	18	11.25	22	12.94		
Month 12	Total Subjs	40		35		A.B	0.274
	>90 mmHg	4	10.00	0	0.00		
	>85-90 mmHg	3	7.50	2	5.71		
	>80-85 mmHg	5	12.50	5	14.29		

Diastolic Blood Pressure: Absolute Change from Baseline (mmHg)

See Figure VIT–2 on page 47.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	359	0.1	13.8	0.4	-9.4	9.3	-23.9	22.1	A.B	0.885
	B	364	0.1	13.6	-0.2	-8.6	9.0	-21.7	23.0		
Month 6	A	300	-0.4	14.0	0.8	-10.1	8.9	-24.8	22.9	A.B	0.673
	B	313	0.2	13.9	-0.2	-8.3	9.6	-23.4	23.4		
Month 9	A	160	0.5	13.5	1.1	-7.6	9.0	-21.2	19.4	A.B	0.503
	B	170	1.4	14.2	2.1	-8.4	10.1	-22.9	24.8		
Month 12	A	40	1.5	16.1	4.4	-8.9	14.1	-27.0	23.6	A.B	0.552
	B	35	0.2	12.6	1.1	-10.1	11.1	-21.4	22.1		

Diastolic Blood Pressure: Increases from Baseline (>4 mmHg)

See Figure VIT–2 on page 47.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Month 3	Total Subjs	359		365		A.B	0.882
	>12 mmHg	72	20.06	66	18.08		
	>8-12 mmHg	35	9.75	33	9.04		
	>4-8 mmHg	35	9.75	36	9.86		
Month 6	Total Subjs	300		314		A.B	0.800
	>12 mmHg	58	19.33	65	20.70		
	>8-12 mmHg	21	7.00	27	8.60		
	>4-8 mmHg	26	8.67	29	9.24		
Month 9	Total Subjs	160		170		A.B	0.659
	>12 mmHg	29	18.12	35	20.59		
	>8-12 mmHg	13	8.12	19	11.18		
	>4-8 mmHg	23	14.38	20	11.76		
Month 12	Total Subjs	40		35		A.B	0.625
	>12 mmHg	12	30.00	7	20.00		
	>8-12 mmHg	4	10.00	4	11.43		
	>4-8 mmHg	4	10.00	2	5.71		

Table Set VIT–3

Weight: Measurements at Scheduled Visits (kg)

See Figure VIT–3 on page 48.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	86.6	15.7	85.9	77.0	96.6	59.8	113.0	A.B	0.878
	B	386	86.8	16.5	86.9	75.6	97.4	60.8	115.6		
Month 3	A	359	86.1	15.1	85.7	75.4	95.7	62.0	113.8	A.B	0.515
	B	365	86.6	17.2	86.6	75.2	97.8	59.2	115.0		
Month 6	A	300	86.1	15.6	86.9	76.0	97.1	59.0	110.5	A.B	0.992
	B	314	86.9	16.0	86.3	75.5	97.2	62.6	114.2		
Month 9	A	160	86.9	16.8	84.1	76.0	99.4	60.5	117.9	A.B	0.682
	B	170	86.2	15.0	86.0	74.3	95.1	62.8	111.8		
Month 12	A	40	84.0	19.5	86.8	72.6	98.5	46.2	114.6	A.B	0.414
	B	35	88.8	20.8	88.0	72.8	104.0	56.0	122.9		

Weight: Absolute Change from Baseline (kg)

See Figure VIT–3 on page 48.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	359	-0.4	20.9	-0.9	-14.3	13.8	-34.3	34.3	A.B	0.720
	B	364	0.2	23.9	-0.0	-16.4	16.7	-39.8	37.9		
Month 6	A	300	0.1	20.9	0.0	-12.7	14.1	-36.5	33.2	A.B	0.707
	B	313	0.2	23.4	0.1	-16.1	14.8	-37.5	44.2		
Month 9	A	160	0.6	22.1	0.5	-14.0	17.9	-34.1	32.3	A.B	0.604
	B	170	-0.4	22.4	-0.6	-15.3	13.7	-38.1	40.3		
Month 12	A	40	-5.3	22.8	-2.5	-23.4	11.3	-44.7	26.6	A.B	0.313
	B	35	0.5	27.7	1.8	-20.4	21.3	-53.3	56.3		

Weight: Percent Change from Baseline (%)

See Figure VIT–3 on page 48.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	359	3.0	27.7	-0.9	-15.6	17.1	-33.6	47.8	A.B	0.762
	B	364	4.3	31.1	-0.0	-17.3	21.6	-37.0	61.0		
Month 6	A	300	3.3	26.5	0.0	-13.1	17.3	-36.0	52.2	A.B	0.743
	B	313	4.5	31.2	0.1	-16.3	18.1	-34.8	63.7		
Month 9	A	160	4.0	27.6	0.5	-16.0	21.8	-37.9	45.7	A.B	0.701
	B	170	3.4	28.9	-0.8	-15.4	16.5	-35.7	56.2		
Month 12	A	40	-3.8	26.8	-2.6	-25.9	14.7	-49.7	42.1	A.B	0.390
	B	35	4.5	33.8	2.5	-21.7	24.3	-45.8	87.6		

Table Set ECG–1

ECG Interpretation: ECG Interpretation

See Figure ECG–1 on page 49.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Baseline	Total Subjs	388		386		A.B	0.929
	Abnormal, clinically signficant	66	17.01	63	16.32		
	Abnormal, not clinically significant	36	9.28	38	9.84		
	Normal	286	73.71	285	73.83		
Month 3	Total Subjs	359		365		A.B	0.192
	Abnormal, clinically signficant	50	13.93	63	17.26		
	Abnormal, not clinically significant	30	8.36	33	9.04		
	Normal	279	77.72	269	73.70		
Month 6	Total Subjs	300		314		A.B	0.345
	Abnormal, clinically signficant	49	16.33	50	15.92		
	Abnormal, not clinically significant	19	6.33	34	10.83		
	Normal	232	77.33	230	73.25		
Month 9	Total Subjs	160		170		A.B	0.653
	Abnormal, clinically signficant	32	20.00	22	12.94		
	Abnormal, not clinically significant	11	6.88	23	13.53		
	Normal	117	73.12	125	73.53		

(Continued on next page.)

(Continued from previous page.)

ECG Interpretation: ECG Interpretation

See Figure ECG–1 on page 49.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Month 12	Total Subjs	40		35		A.B	0.063
	Abnormal, clinically signficant	3	7.50	12	34.29		
	Abnormal, not clinically significant	7	17.50	2	5.71		
	Normal	30	75.00	21	60.00		

ECG Interpretation: Change from Baseline in ECG Interpretation

See Figure ECG–1 on page 49.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Month 3	Total Subjs	359		364		A.B	0.243
	Worse	67	18.66	76	20.88		
	Same	210	58.50	217	59.62		
	Better	82	22.84	71	19.51		
Month 6	Total Subjs	300		313		A.B	0.314
	Worse	56	18.67	69	22.04		
	Same	178	59.33	181	57.83		
	Better	66	22.00	63	20.13		
Month 9	Total Subjs	160		170		A.B	0.612
	Worse	35	21.88	35	20.59		
	Same	93	58.12	97	57.06		
	Better	32	20.00	38	22.35		
Month 12	Total Subjs	40		35		A.B	0.049
	Worse	5	12.50	13	37.14		
	Same	28	70.00	17	48.57		
	Better	7	17.50	5	14.29		

Table Set ECG–2

ECG: PR Interval and QRS Interval: PR Interval: Measurements at Scheduled Visits (msec)

See Figure ECG–2 on page 50.

		Total		Std							P-
	Trt	Subjs	Mean	Dev	Median	Q1	Q3	P5	P95	Contrast	Value
Baseline	A	388	175.3	31.5	175.6	157.4	192.6	123.7	227.7	A.B	0.826
	B	386	174.2	30.3	174.9	153.5	196.5	127.1	221.1		
Month 3	A	359	173.5	28.4	174.0	151.9	195.0	127.4	219.2	A.B	0.308
	B	365	176.2	31.0	176.2	153.1	196.2	129.0	227.4		
Month 6	A	300	173.9	28.6	173.6	154.3	193.8	125.2	224.4	A.B	0.901
	B	314	172.7	28.7	173.9	155.3	191.7	125.1	214.9		
Month 9	A	160	173.3	29.6	172.5	153.2	190.0	125.9	228.1	A.B	0.067
	B	170	178.4	27.8	177.9	159.7	200.2	127.5	221.9		
Month 12	A	40	175.5	34.8	173.8	150.1	203.7	118.5	236.6	A.B	0.339
	B	35	167.8	30.4	163.9	149.2	185.1	115.1	241.4		

ECG: PR Interval and QRS Interval: PR Interval: Absolute Change from Baseline (msec)

See Figure ECG–2 on page 50.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	359	-1.8	40.8	-0.1	-28.7	25.6	-70.1	59.4	A.B	0.715
	B	364	1.2	44.4	0.7	-30.1	29.8	-69.8	73.8		
Month 6	A	300	-1.2	43.3	0.2	-27.7	28.0	-72.9	70.3	A.B	0.780
	B	313	-1.6	41.5	-1.7	-28.4	25.3	-64.1	62.7		
Month 9	A	160	-0.9	43.7	-6.9	-28.6	27.2	-70.5	77.9	A.B	0.414
	B	170	1.6	41.3	-1.2	-26.9	31.1	-64.1	68.4		
Month 12	A	40	2.1	48.2	5.6	-38.6	37.8	-68.6	78.6	A.B	0.247
	B	35	-10.1	41.3	-24.7	-38.0	16.1	-66.9	75.5		

ECG: PR Interval and QRS Interval: QRS Interval: Measurements at Scheduled Visits (msec)

See Figure ECG–2 on page 50.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	98.7	22.0	98.2	83.1	114.6	62.8	133.6	A.B	0.367
	B	386	100.4	20.6	99.6	87.4	114.5	67.1	134.7		
Month 3	A	359	100.0	21.6	98.6	86.1	115.1	64.4	136.6	A.B	0.332
	B	365	101.6	21.1	101.8	87.9	114.3	67.3	139.7		
Month 6	A	300	100.1	22.2	100.7	83.5	116.1	63.1	136.8	A.B	0.861
	B	314	99.9	20.5	101.0	86.1	113.4	67.4	135.8		
Month 9	A	160	98.6	20.4	99.1	84.9	113.4	65.0	130.9	A.B	0.353
	B	170	100.7	21.4	102.4	88.1	114.8	61.0	133.6		
Month 12	A	40	97.3	18.4	94.6	83.2	115.4	72.2	128.6	A.B	0.401
	B	35	92.1	25.5	92.3	80.5	106.8	36.5	136.6		

ECG: PR Interval and QRS Interval: QRS Interval: Absolute Change from Baseline (msec)

See Figure ECG–2 on page 50.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	359	1.5	31.8	0.8	-20.0	22.5	-51.2	54.3	A.B	0.976
	B	364	1.1	30.1	1.0	-18.2	20.1	-48.4	53.7		
Month 6	A	300	1.3	30.9	1.5	-20.0	21.6	-49.7	51.6	A.B	0.304
	B	313	-1.0	28.9	-0.6	-20.1	17.8	-50.2	47.5		
Month 9	A	160	-0.4	30.6	0.2	-21.5	21.3	-53.0	49.3	A.B	0.851
	B	170	0.3	30.0	2.9	-22.0	17.7	-47.7	49.0		
Month 12	A	40	-3.0	28.7	0.3	-20.8	13.5	-55.6	43.5	A.B	0.610
	B	35	-7.4	32.5	-4.9	-25.9	15.3	-63.2	55.4		

Table Set ECG–3

ECG: RR Interval and QTc Interval (Fridericia): RR Interval: Measurements at Scheduled Visits (msec)

See Figure ECG–3 on page 51.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	974.3	142.3	974.6	867.0	1074.3	750.4	1207.6	A.B	0.878
	B	386	971.2	135.6	975.9	884.9	1065.2	752.5	1198.0		
Month 3	A	359	968.1	140.2	971.4	871.0	1062.4	729.2	1208.2	A.B	0.102
	B	365	987.1	133.3	989.7	893.0	1077.7	767.9	1196.0		
Month 6	A	300	967.5	135.6	966.2	880.1	1052.6	738.8	1196.8	A.B	0.073
	B	314	985.0	140.1	989.4	894.4	1086.7	735.5	1199.8		
Month 9	A	160	1000.2	145.3	1008.1	912.7	1102.8	751.1	1242.7	A.B	0.108
	B	170	975.6	129.9	978.3	904.2	1071.7	758.5	1184.7		
Month 12	A	40	998.4	144.1	968.1	903.3	1094.5	785.2	1278.7	A.B	0.824
	B	35	1005.3	151.3	994.7	901.7	1082.4	788.9	1312.4		

ECG: RR Interval and QTc Interval (Fridericia): RR Interval: Absolute Change from Baseline (msec)

See Figure ECG–3 on page 51.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	359	-7.6	191.7	-2.0	-154.1	125.8	-335.2	314.4	A.B	0.138
	B	364	14.4	194.9	7.0	-131.8	145.5	-287.4	348.4		
Month 6	A	300	-8.0	204.0	-10.0	-159.1	131.2	-343.6	327.4	A.B	0.157
	B	313	12.3	188.7	7.8	-97.2	139.4	-305.3	334.9		
Month 9	A	160	29.7	202.8	37.0	-103.4	150.5	-314.1	391.6	A.B	0.199
	B	170	3.7	197.5	-0.7	-135.9	138.1	-306.2	329.2		
Month 12	A	40	35.8	196.5	39.3	-117.6	185.5	-259.8	383.7	A.B	0.807
	B	35	29.5	223.0	36.5	-160.4	221.2	-328.1	432.1		

ECG: RR Interval and QTc Interval (Fridericia): QTc Interval (Fridericia): Measurements at Scheduled Visits (msec)

See Figure ECG–3 on page 51.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Baseline	A	388	412.0	31.4	412.5	390.5	433.5	358.6	462.5	A.B	0.426
	B	386	409.7	31.8	410.5	385.8	432.9	356.3	457.0		
Month 3	A	359	409.1	29.0	410.1	390.1	430.2	360.4	456.3	A.B	0.812
	B	365	409.0	32.4	408.5	388.2	431.2	354.0	459.8		
Month 6	A	300	409.0	31.8	406.8	386.6	430.6	356.7	464.4	A.B	0.508
	B	314	410.3	30.0	411.5	388.5	431.1	360.7	461.3		
Month 9	A	160	409.0	30.7	407.3	388.6	427.6	365.1	463.2	A.B	0.278
	B	170	410.6	30.1	410.6	394.0	430.7	354.1	460.4		
Month 12	A	40	410.7	28.0	417.4	396.1	427.3	355.5	453.2	A.B	0.195
	B	35	403.2	29.1	397.2	382.2	424.3	356.4	445.5		

ECG: RR Interval and QTc Interval (Fridericia): QTc Interval (Fridericia): Absolute Change from Baseline (msec)

See Figure ECG–3 on page 51.

	Trt	Total Subjs	Mean	Std Dev	Median	Q1	Q3	P5	P95	Contrast	P-Value
Month 3	A	359	-2.8	41.5	-3.9	-30.7	24.2	-71.3	65.5	A.B	0.601
	B	364	-1.2	47.0	-0.8	-32.1	29.1	-82.3	74.8		
Month 6	A	300	-3.5	44.6	-6.6	-35.5	27.0	-73.9	74.3	A.B	0.203
	B	313	1.1	44.8	-2.1	-28.4	33.2	-70.9	73.2		
Month 9	A	160	-3.6	44.2	-6.5	-35.7	21.5	-73.3	69.8	A.B	0.136
	B	170	2.2	44.7	3.5	-25.3	29.1	-79.5	72.7		
Month 12	A	40	5.3	40.1	12.7	-14.9	30.8	-64.7	70.5	A.B	0.146
	B	35	-5.2	41.8	-8.1	-29.6	15.9	-82.9	51.0		

5.2 Concomitant Medications

Table Set CONMEDS–1

Standard of Care Medications: By Time of First Reported Use

See Figure CONMEDS–1 on page 52.

		Treatment Group					
		A		B			P-
	Value	N	%	N	%	Contrast	Value
Statin therapy	Total Subjs	388		387		A.B	0.154
	Reported at baseline	184	47.42	198	51.16		
	Added after randomization	36	9.28	41	10.59		
	Not reported	168	43.30	148	38.24		
Aspirin	Total Subjs	388		387		A.B	0.404
	Reported at baseline	213	54.90	193	49.87		
	Added after randomization	25	6.44	29	7.49		
	Not reported	150	38.66	165	42.64		
Beta-blocker	Total Subjs	388		387		A.B	0.886
	Reported at baseline	154	39.69	162	41.86		
	Added after randomization	41	10.57	37	9.56		
	Not reported	193	49.74	188	48.58		
ACE inhibitor	Total Subjs	388		387		A.B	0.039
	Reported at baseline	214	55.15	204	52.71		
	Added after randomization	52	13.40	38	9.82		
	Not reported	122	31.44	145	37.47		
Angiotensin II receptor blocker	Total Subjs	388		387		A.B	0.033
	Reported at baseline	126	32.47	144	37.21		
	Added after randomization	16	4.12	25	6.46		
	Not reported	246	63.40	218	56.33		

Chapter 6

Study Endpoints

Table Set ENDPT–1

All-Cause Mortality: Event Probability over Time

See Figure ENDPT–1 on page 54.

Months	Trt	nRisk	nEvents	% w/ Event	95% CI
0	A	388	0	0.3	(0.0, 0.8)
	B	387	0	0.0	(0.0, 0.0)
1	A	380	8	2.1	(0.6, 3.5)
	B	380	6	1.6	(0.3, 2.8)
2	A	370	13	3.4	(1.5, 5.1)
	B	373	10	2.6	(1.0, 4.2)
3	A	360	19	4.9	(2.7, 7.1)
	B	366	11	2.9	(1.2, 4.5)
4	A	355	22	5.7	(3.4, 8.0)
	B	351	16	4.2	(2.2, 6.2)
5	A	339	27	7.1	(4.5, 9.6)
	B	339	18	4.7	(2.6, 6.9)
6	A	310	36	9.6	(6.5, 12.5)
	B	323	20	5.3	(3.0, 7.6)
7	A	276	39	10.5	(7.3, 13.5)
	B	293	24	6.5	(4.0, 9.0)
8	A	226	46	12.9	(9.3, 16.4)
	B	244	28	7.9	(5.0, 10.7)
9	A	178	48	13.8	(10.1, 17.5)
	B	188	31	9.2	(6.0, 12.3)
10	A	123	48	13.8	(10.1, 17.5)
	B	124	32	9.8	(6.4, 13.0)
11	A	71	50	15.7	(11.1, 20.0)
	B	74	32	9.8	(6.4, 13.0)
12	A	42	51	17.5	(11.7, 22.9)
	B	43	33	11.5	(6.7, 16.1)

Index of Figures and Tables

Page numbers for main material appear in normal (unslanted) type; page numbers for supporting material, if any, are given in italics.